

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [editorial.bmjopen@bmj.com](mailto:editorial.bmjopen@bmj.com)

# BMJ Open

## Splenectomy correlates with increased risk of empyema: a population-based cohort study in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015101
Article Type:	Research
Date Submitted by the Author:	11-Nov-2016
Complete List of Authors:	Lin, Hsien-Feng; China Medical University Hospital, ; Liao, Kuan-Fu Chang, Ching-Mei Lin, Cheng-Li Lai, Shih-Wei; China Medical University Hospital, Department of Family Medicine
<b>Primary Subject Heading</b>:	General practice / Family practice
Secondary Subject Heading:	Gastroenterology and hepatology
Keywords:	empyema, splenectomy, Taiwan National Health Insurance Program

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Type of manuscript: Original article

□ Manuscript title: **Splenectomy correlates with increased risk of empyema: a population-based cohort study in Taiwan**

□ Running head: splenectomy and empyema

• Authors' full names:

Hsien-Feng Lin MD and MS<sup>1,2</sup>; Kuan-Fu Liao MD and MS<sup>3,4,5</sup>; Ching-Mei Chang RN and MSN<sup>6</sup>; Cheng-Li Lin MS<sup>7,8</sup>; Shih-Wei Lai MD<sup>2,7</sup>

• (The first three authors contributed equally to this study)

• <sup>1</sup>School of Chinese Medicine, <sup>5</sup>Graduate Institute of Integrated Medicine, and <sup>7</sup>College of Medicine, China Medical University, Taichung, Taiwan.

• <sup>3</sup>Department of Internal Medicine, Taichung Tzu Chi General Hospital, Taichung, Taiwan

• <sup>4</sup>College of Medicine, Tzu Chi University, Hualien, Taiwan

• <sup>2</sup>Department of Family Medicine and <sup>8</sup>Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan.

• <sup>6</sup>Assistant Professor and Deputy Director, Department of Nursing, Tungs Taichung Metro Harbor Hospital, Taichung<sup>7</sup>, Taiwan

• Corresponding author: Shih-Wei Lai, Department of Family Medicine, China Medical University Hospital, No 2, Yuh-Der Road, Taichung City, 404, Taiwan

Phone: 886-4-2205-2121; Fax: 886-4-2203-3986

E-mail: wei@mail.cmuh.org.tw

Words count: 225 in abstract; 2430 in text; 4 tables; 32 references

## ABSTRACT

**Objectives.** Little is known about the risk of empyema in patients with splenectomy. We investigate the relationship between splenectomy and empyema in Taiwan.

**Methods.** We conducted a population-based cohort analysis using the hospitalization dataset of the Taiwan National Health Insurance Program. There were 13193 subjects aged 20 to 84 years who were newly diagnosed with splenectomy in 2000 to 2010 as the splenectomy group and 52464 randomly selected subjects without splenectomy as the non-splenectomy group. Both groups were matched by sex, age, comorbidities, and hospitalization year of performing splenectomy. The incidence of empyema at the end of 2011 was calculated. The multivariable Cox proportional hazards regression model was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for empyema associated with splenectomy and other comorbidities. **Results.** The overall incidence rate of empyema was 2.56-fold higher in the splenectomy group than that in the non-splenectomy group (8.85 vs. 3.46 per 1,000 person-years, 95% CI 2.44, 2.69). After adjusted for confounders, the adjusted HR of empyema was 2.89 in subjects with splenectomy (95%CI 2.60, 3.22), compared with subjects without splenectomy. In further analysis, even in the absence of comorbidities studied, the HR was 4.52 for those with splenectomy alone (95% CI=3.80, 5.37). **Conclusions.** Patients with splenectomy are associated with 2.89-fold increased risk of empyema. Even in the absence of comorbidities, the risk remains high.

**Keywords:** empyema; splenectomy; Taiwan National Health Insurance Program

### Strengths and limitations of this study.

1. This is the first original holistic study on the association between splenectomy and empyema.
2. We used a hospitalization dataset with a large sample size and great statistical power.
3. Some traditional behavior risk factors including alcohol consumption and cigarette smoking were not recorded due to the inherent limitation of this insurance database.
4. The underlying causes for splenectomy in this present study were not recorded due to the inherent limitation of this insurance database.
5. Such a study design does not permit to conclude a substantial causality.

## INTRODUCTION

Empyema is a suppurative infection of the pleural space. The creation of empyema can be divided into two distinct mechanisms. Empyema occurs most commonly after pneumonia, with direct spread of organisms into the pleural space. This occurs in approximately 1% to 5% of pneumonias.<sup>1,2</sup> The other mechanism occurs after surgery, most commonly of the thorax, esophagus, lung or heart. Empyema is an ancient disease that continues to be an important clinical problem nowadays. Despite the centuries of learned experience, the appearance of antibiotics and the use of different pneumococcal vaccines, empyema remains the most common complication of pneumonia and an important cause of morbidity worldwide.<sup>3</sup>

The human spleen mainly serves an immune function against invading microorganisms.<sup>4,5</sup> The immunologic and hematologic functions of the spleen in humans are well known. Specifically, the spleen protects against infections mediated by innate and adaptive immunity.<sup>6,7</sup> Patients with splenectomy are more likely than those without splenectomy to suffer severe life-threatening infections. Splenectomy is associated with increased risk of some diseases, including pulmonary tuberculosis, type 2 diabetes mellitus, pyogenic liver abscess, renal and perinephric abscesses, and acute pancreatitis,<sup>8-12</sup> but empyema has not yet been studied.

We rationally hypothesize an association between splenectomy and empyema due to the immunocompromised condition caused by splenectomy, which can further increase the risk of microorganism invasion of the pleural space. However, published literature from epidemiological studies on this issue is scarce. Given that splenectomy is associated with overwhelming postsplenectomy infections and empyema carries a potential fatality, exploring the risk of empyema in patients with splenectomy may have significant clinical and public health implications. Therefore, to explore whether there is an association between splenectomy and empyema, we conducted a

1  
2  
3 nationwide cohort study using the hospitalization dataset of the Taiwan National  
4  
5 Health Insurance Program.  
6  
7

## 8 **METHODS**

### 9 **Study design and data source**

10  
11  
12 Taiwan is an independent country with more than 23 million people. We conducted  
13  
14 a population-based cohort study using insurance claim data from the Taiwan National  
15  
16 Health Insurance Program which covers 99% of the whole Taiwan population since  
17  
18 1995.<sup>13</sup> The details of the insurance program have been well written in previous  
19  
20 studies.<sup>14-17</sup> The study was approved by the Institutional Review Board of China  
21  
22 Medical University and Hospital in Taiwan (CMUH-104-REC2-115).  
23  
24

### 25 **Sampled Participants**

26  
27 Using the hospitalization dataset of the Taiwan National Health Insurance Program,  
28  
29 all hospitalized subjects aged 20 to 84 who performed splenectomy (International  
30  
31 Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9 procedure  
32  
33 code 41.5) between January 1, 2000 and December 31, 2010, were identified as the  
34  
35 splenectomy group. The date for performing splenectomy was defined as the index  
36  
37 date. For each subject with splenectomy, 4 subjects without splenectomy were  
38  
39 randomly selected from the same database as the non-splenectomy group. Both  
40  
41 groups were matched by sex, age (every 5-year span), comorbidities, and the  
42  
43 hospitalization year of performing splenectomy. To reduce the biased results, subjects  
44  
45 with empyema diagnosis (ICD-9 codes 510, 511.1, 511.8, and 511.9) within one  
46  
47 month after performing splenectomy were excluded from the study.  
48  
49  
50

### 51 **Outcome and Comorbidities**

52  
53 The main outcome was a new diagnosis of empyema based on hospital discharge  
54  
55 registries during the follow-up period. Each subject was monitored from the index  
56  
57 date until being diagnosed with empyema, or being censored because of loss to  
58  
59  
60

1  
2  
3 follow-up, death, or withdrawal from insurance, or to the end of December 31, 2011.

4  
5 Comorbidities investigated in the study were included as follows: alcohol-related  
6  
7 diseases, cancers, chronic kidney diseases, chronic liver diseases (including cirrhosis,  
8  
9 alcoholic liver damage, hepatitis B, hepatitis C, and other chronic hepatitis), chronic  
10  
11 obstructive pulmonary diseases, and diabetes mellitus. All comorbidities were  
12  
13 diagnosed with ICD-9 codes, which have been well assessed in previous studies.<sup>18-21</sup>

### 14 15 16 **Statistical analysis**

17  
18 The differences between sex, age, and comorbidities between the splenectomy group  
19  
20 and the non-splenectomy group were compared by using the Chi-square test for  
21  
22 categorical variables, and *t* test for continuous variables. Follow-up time  
23  
24 (person-years) was used to estimate the incidence rate and incidence rate ratio (IRR)  
25  
26 with 95% confidence interval (CI) of splenectomy group to non-splenectomy group  
27  
28 using Poisson regression, by sex, age, and follow-up period. The multivariable Cox  
29  
30 proportional hazards regression model was used to estimate the hazard ratio (HR)  
31  
32 with 95% confidence interval (CI) of empyema associated with splenectomy and  
33  
34 other comorbidities after simultaneously adjusted for variables found to be significant  
35  
36 in the univariable Cox proportion hazard regression model. The proportional hazard  
37  
38 model assumption was examined by using a test of scaled Schoenfeld residuals. In the  
39  
40 model evaluating empyema risk throughout the overall follow-up period, results of the  
41  
42 test revealed a significant relationship between Schoenfeld residuals for splenectomy  
43  
44 and follow-up time, suggesting the proportionality assumption was violated (*P* value  
45  
46 < 0.001). In the subsequent analysis, we stratified the follow-up period to deal with  
47  
48 the violation of proportional hazard assumption (Please see Table 2). All statistical  
49  
50 analyses were performed using SAS 9.2 (SAS Institute, Cary, North Carolina, USA).  
51  
52  
53  
54  
55  
56 Two-tailed *P* < 0.05 was considered statistically significant.  
57  
58  
59  
60

## RESULTS

### Baseline information of the study population

Table 1 discloses the baseline information of the study population. There were 13193 subjects with splenectomy and 52464 subjects without splenectomy during the study period, with similar distributions in sex and age. The mean ages (mean  $\pm$  standard deviation) were  $52.8 \pm 17.2$  years in the splenectomy group and  $52.5 \pm 17.2$  years in the non-splenectomy group ( $t$  test,  $P = 0.05$ ). The mean follow-up periods (mean  $\pm$  standard deviation) were  $4.37 \pm 3.44$  years in the splenectomy group and  $5.75 \pm 3.32$  years in the non-splenectomy group ( $t$  test,  $P < 0.001$ ). There was no significant difference in the prevalence of comorbidities studied between the splenectomy group and the non-splenectomy group (Chi-square test,  $P > 0.05$  for all).

### Incidence of empyema stratified by sex, age, and follow-up period

Table 2 discloses the incidence rates of empyema. At the end of the cohort study, the overall incidence rate of empyema was 2.56-fold higher in the splenectomy group than that in the non-splenectomy group (8.85 vs. 3.46 per 1,000 person-years, 95% CI 2.44, 2.69). The incidence rates of empyema, as stratified by sex, age, and follow-up period, were all higher in the splenectomy group than those in the non-splenectomy group. The incidence rates of empyema increased with age in both groups, with the highest in the splenectomy group aged 65 to 84 years (19.2 per 1,000 person-years). Stratified analysis by follow-up period disclosed that the incidence rates of empyema decreased with the follow-up time in both groups. The risk of empyema in the splenectomy group was significantly higher in the first 5 years of follow-up (incidence rate ratio 2.87, 95% CI 2.73, 3.01). However, the risk of empyema still existed in the splenectomy group even after 5 years (incidence rate ratio 1.73, 95% CI 1.60, 1.88).

### Hazard ratio of empyema associated with splenectomy and other comorbidities



1  
2  
3 Table 3 discloses the HR of empyema associated with splenectomy and other  
4 comorbidities. Only those found significantly in the univariable analysis were further  
5 examined in the multivariable analysis. After adjusted for age, sex, alcohol-related  
6 diseases, cancers, chronic kidney diseases, chronic liver diseases, chronic obstructive  
7 pulmonary disease, and diabetes mellitus, the multivariable Cox proportional hazards  
8 regression model disclosed that the adjusted HR of empyema was 2.89 in subjects  
9 with splenectomy (95% CI 2.60, 3.22), compared with subjects without splenectomy.  
10 Male (HR 1.51, 95 % CI 1.35, 1.68), alcohol-related diseases (HR 2.25, 95 % CI  
11 1.76, 2.86), cancers (HR 1.92, 95 % CI 1.71, 2.17), chronic kidney disease (HR 2.13,  
12 95 % CI 1.67, 2.70), chronic liver diseases (HR 1.90, 95 % CI 1.68, 2.14), chronic  
13 obstructive pulmonary diseases (HR 1.75, 95 % CI 1.48, 2.07), and diabetes  
14 mellitus (HR 1.85, 95 % CI 1.65, 2.07) were also associated with empyema. Every  
15 one-year increase in age was associated with a 1.05-fold increased risk of empyema  
16 (95% CI 1.05, 1.06).  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

### 33 **Interaction effect on risk of empyema between splenectomy and other** 34 **comorbidities** 35

36  
37 Table 4 discloses interaction effect on risk of empyema between splenectomy and  
38 other comorbidities including alcohol-related diseases, cancers, chronic kidney  
39 diseases, chronic liver diseases, chronic obstructive pulmonary diseases, and diabetes  
40 mellitus. As a reference of subjects without splenectomy and without any comorbidity,  
41 the adjusted HR of empyema was 4.52 for subjects with splenectomy alone and  
42 without any comorbidity (95% CI 3.80, 5.37). The HR markedly increased to 8.23 for  
43 those with splenectomy and comorbid with any comorbidity (95% CI 6.98, 9.70). It  
44 means that there is an interaction effect on risk of empyema between splenectomy and  
45 other comorbidities.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

A review by Sinwar found that the duration between splenectomy and onset of overwhelming post-splenectomy infection could range from less than 1 week to more than 20 years.<sup>22</sup> To diminish biased results, we excluded patients who underwent splenectomy within 1 month of empyema diagnosis to ensure that splenectomy truly preceded the onset of empyema. In this population-based cohort study, we noticed that splenectomy was associated with increased hazard ratio of empyema (adjusted HR 2.89). To the best of our knowledge, this is the first population-based cohort study to examine this issue. Some studies have found that splenectomy is associated with increased risk of some diseases. Lai et al. found that the adjusted odds ratio of acute pancreatitis was 2.90 for subjects with splenectomy (95% CI, 1.39–6.05) compared with subjects without splenectomy,<sup>12</sup> the adjusted hazard ratio of renal and perinephric abscesses was 2.24 for the splenectomy group (95% CI, 1.30–3.88) when compared with the non-splenectomy group,<sup>11</sup> the adjusted hazard ratio of pyogenic liver abscess was 3.89 in subjects with splenectomy (95% confidence interval, 3.20–4.72) when compared with subjects without splenectomy,<sup>10</sup> and the odds of pulmonary tuberculosis were 1.91 in patients with splenectomy (95% CI 1.06–3.44) compared with the participants without splenectomy.<sup>8</sup>

Extensive evidence has revealed that the human spleen mainly serves a protective role against invading microorganisms on the basis of bactericidal capacity of lymphoid cells and macrophages and the humoral immune response.<sup>6,23-25</sup> Upon removal of the spleen, normal immune functions, such as phagocytic activities and the humoral immune response, may be significantly changed. Therefore, impaired immune functions after splenectomy may increase the risk of life-threatening infection and empyema.

In our study, the risk of empyema in the splenectomy group was higher in the first

1  
2  
3 5 years of follow-up than after 5 years (incidence rate ratio 2.87 vs 1.72). However,  
4  
5 the risk of empyema still existed in the splenectomy group even after 5 years. These  
6  
7 findings are compatible with previous studies showing that the majority of severe  
8  
9 infections occur within the first 3 years after splenectomy, and, although the risk  
10  
11 declines over time, the risk might last for more than 5 years after splenectomy.<sup>26-28</sup>  
12  
13 The mechanism remains unknown. We speculate that with time, the immune system  
14  
15 could develop ways to compensate or overcome these immune deficits. So the risk of  
16  
17 empyema in the splenectomy group was higher in the first 5 years of follow-up.  
18  
19 Future studies are needed to confirm this hypothesis.  
20  
21

22  
23 In this study, after controlling for potential confounding factors, we also observed  
24  
25 that patients with splenectomy were at increased risk of empyema (adjusted HR 2.89).  
26  
27 The HR seems to be higher than that observed for other comorbidities. The HR was  
28  
29 not confounded by other studied comorbidities because there was no significant  
30  
31 difference in the prevalence of comorbidities between the splenectomy group and the  
32  
33 non-splenectomy group, so the increased risk of empyema in patients with  
34  
35 splenectomy cannot be totally attributable to the effect of comorbidities. In further  
36  
37 analysis, even in the absence of any comorbidity, patients with splenectomy still had a  
38  
39 higher risk of empyema than those without splenectomy (adjusted HR 4.52). This  
40  
41 indicates splenectomy may have a unique role on risk of empyema independent of  
42  
43 other comorbidities. These findings are compatible with the literature showing that  
44  
45 patients with splenectomy are not only more prone than those without splenectomy to  
46  
47 suffer severe life-threatening infection due to the immunocompromised condition  
48  
49 caused by splenectomy<sup>29,30</sup> but are also at an increased risk of developing empyema.  
50  
51

52  
53 Some limitations in the present study deserve discussion. First, some traditional  
54  
55 behavior risk factors including alcohol consumption and cigarette smoking were not  
56  
57 recorded due to the inherent limitation of this insurance database. We used  
58  
59

1  
2  
3 alcohol-related diseases instead of alcohol consumption and chronic obstructive  
4  
5 pulmonary disease instead of cigarette smoking. Second, the underlying causes for  
6  
7 splenectomy in this present study were not recorded due to the inherent limitation of  
8  
9 this insurance database. Splenectomy is commonly performed in certain disorders and  
10  
11 diseases, such as hematological disorders, gastric cancer, or trauma, so these  
12  
13 background conditions might confound the results. Whether the reasons for  
14  
15 splenectomy are associated with empyema cannot be clarified in this study. Third,  
16  
17 such a study design does not permit to conclude a substantial causality. Further  
18  
19 prospective studies are needed to confirm our findings.  
20  
21  
22

23 The strength of this study is that this is the first original holistic study on the  
24  
25 association between splenectomy and empyema. Although the underlying mechanism  
26  
27 linking splenectomy and empyema cannot be completely determined, our findings are  
28  
29 clinically important. In addition, we used a hospitalization dataset with a large sample  
30  
31 size and great statistical power. The diagnosis codes of included comorbidities have  
32  
33 been documented in previous studies.<sup>31,32</sup> The study design and statistical methods are  
34  
35 described in detail. Our results were relatively convincing because the splenectomy  
36  
37 group and the non-splenectomy group had similar distributions of studied  
38  
39 comorbidities. Therefore, the confounding effects of these comorbidities on risk of  
40  
41 empyema should be minimal.  
42  
43  
44

45 We conclude that patients with splenectomy are associated with 2.89-fold increased  
46  
47 risk of empyema, particularly comorbid with other conditions, including  
48  
49 alcohol-related diseases, cancers, chronic kidney diseases, chronic liver diseases,  
50  
51 chronic obstructive pulmonary diseases, and diabetes mellitus. Even in the absence of  
52  
53 comorbidities, the risk remains high.  
54  
55  
56  
57  
58  
59  
60

### **Acknowledgement**

This study was supported in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037), National Research Program for Biopharmaceuticals (NRPB) Stroke Clinical Trial Consortium (MOST 105-2325-B-039 -003), Tseng-Lien Lin Foundation in Taichung in Taiwan, Taiwan Brain Disease Foundation in Taipei in Taiwan, and Katsuzo and Kiyoo Aoshima Memorial Funds in Japan. These funding agencies did not influence the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### **Specific author contributions**

Hsien-Feng Lin and Kuan-Fu Liao substantially planned and conducted this study, participated in the data interpretation, and also critically revised the article.

Ching-Mei Chang and Cheng-Li Lin conducted the data analysis and critically revised the article.

Shih-Wei Lai substantially planned and conducted this study, contributed to the conception of the article, initiated the draft of the article, and critically revised the article.

### **Conflict of Interest Statement**

The authors disclose no conflicts of interest.

**REFERENCES**

1. Ahmed RA, Marrie TJ, Huang JQ. Thoracic empyema in patients with community-acquired pneumonia. *Am J Med* 2006;119:877-83.
2. Shields T, Locicero J, Ponn R, Rusch V, eds. *General Thoracic Surgery*, 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2005:823.
3. Septimus EJ. Pleural effusion and empyema. In: Mandell GL, Bennet JE, Mandell RD, editors. *Douglas and Bennett's principles and practice of infectious diseases*. Edinburgh: Churchill Livingstone; 2009. pp. 917-24.
4. Spencer RP, Pearson HA. The spleen as a hematological organ. *Semin Nucl Med*. 1975;5:95-102.
5. Trigg ME. Immune function of the spleen. *South Med J*. 1979;72:593-9.
6. Jirillo E, Mastronardi ML, Altamura M, Munno I, Miniello S, Urgesi G, et al. The immunocompromised host: immune alterations in splenectomized patients and clinical implications. *Curr Pharm Des*. 2003;9:1918-23.
7. Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. *Lancet*. 2011;378:86-97.
8. Lai SW, Wang IK, Lin CL, Chen HJ, Liao KF. Splenectomy correlates with increased risk of pulmonary tuberculosis: a case-control study in Taiwan. *Clin Microbiol Infect* 2014;20:764-7.
9. Wu SC, Fu CY, Muo CH, Chang YJ. Splenectomy in trauma patients is associated with an increased risk of postoperative type II diabetes: a nationwide population-based study. *Am J Surg* 2014;208:811-6.
10. Lai SW, Lai HC, Lin CL, Liao KF. Splenectomy Correlates With Increased Risk of Pyogenic Liver Abscess: A Nationwide Cohort Study in Taiwan. *J Epidemiol* 2015;25:561-6.
11. Lai SW, Lin HF, Lin CL, Liao KF. Splenectomy and risk of renal and perinephric abscesses: A population-based cohort study in Taiwan. *Medicine* 2016;95:31(e4438).
12. Lai SW, Lin CL, Liao KF. Splenectomy Correlates With Increased Risk of Acute Pancreatitis: A Case-Control Study in Taiwan. *J Epidemiol* 2016;26:488-92.
13. National Health Insurance Research Database. Taiwan. <http://nhird.nhri.org.tw/en/index.html> [cited in 2016 September 1, English version].
14. Lai SW, Liao KF, Liao CC, Muo CH, Liu CS, Sung FC. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. *Medicine* 2010;89:295-9.
15. Chen HY, Lai SW, Muo CH, Chen PC, Wang IJ. Ethambutol-induced optic

- 1  
2  
3 neuropathy: a nationwide population-based study from Taiwan. *Br J Ophthalmol*  
4 2012;96:1368-71.  
5  
6 16. Yang SP, Muo CH, Wang IK, et al. Risk of type 2 diabetes mellitus in female  
7 breast cancer patients treated with morphine: A retrospective population-based  
8 time-dependent cohort study. *Diabetes Res Clin Pract* 2015;110:285-90.  
9  
10 17. Tsai TY, Lin CC, Peng CY, et al. The association between biliary tract  
11 inflammation and risk of digestive system cancers: A population-based cohort  
12 study. *Medicine* 2016;95:31(e4427).  
13  
14 18. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular  
15 carcinoma in diabetic patients and risk reduction associated with anti-diabetic  
16 therapy: a population-based cohort study. *Am J Gastroenterol* 2012;107:46-52.  
17  
18 19. Liao KF, Lin CL, Lai SW, Chen WC. Zolpidem Use Associated With Increased  
19 Risk of Pyogenic Liver Abscess: A Case-Control Study in Taiwan. *Medicine*  
20 2015;94:32(e1302).  
21  
22 20. Wong TS, Liao KF, Lin CM, Lin CL, Chen WC, Lai SW. Chronic Pancreatitis  
23 Correlates With Increased Risk of Cerebrovascular Disease: A Retrospective  
24 Population-Based Cohort Study in Taiwan. *Medicine* 2016;95:15(e3266).  
25  
26 21. Liao KF, Lai SW, Lin CL, Chien SH. Appendectomy correlates with increased risk  
27 of pyogenic liver abscess: A population-based cohort study in Taiwan. *Medicine*  
28 2016;95:26(e4015).  
29  
30 22. Sinwar PD. Overwhelming post splenectomy infection syndrome—review study.  
31 *Int J Surg.* 2014;12:1314–6.  
32  
33 23. Eibl M. Immunological consequences of splenectomy. *Prog Pediatr Surg.*  
34 1985;18:139–45.  
35  
36 24. Van Rooijen N. The humoral immune response in the spleen. *Res Immunol.*  
37 1991;142:328–30.  
38  
39 25. Altamura M, Caradonna L, Amati L, Pellegrino NM, Urgesi G, Miniello S.  
40 Splenectomy and sepsis: the role of the spleen in the immune-mediated bacterial  
41 clearance. *Immunopharmacol Immunotoxicol.* 2001;23:153–61.  
42  
43 26. Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among  
44 post-splenectomy patients. *J Infect.* 2001;43:182–6.  
45  
46 27. Kyaw MH, Holmes EM, Toolis F, Wayne B, Chalmers J, Jones IG, et al.  
47 Evaluation of severe infection and survival after splenectomy. *Am J Med.*  
48 2006;119:276 e1–7.  
49  
50 28. Dendle C, Sundararajan V, Spelman T, Jolley D, Woolley I. Splenectomy  
51 sequelae: an analysis of infectious outcomes among adults in Victoria. *Med J Aust.*  
52 2012;196:582–6.  
53  
54 29. Di Cataldo A, Puleo S, Li Destri G, Racalbuto A, Trombatore G, Latteri F, et al.  
55  
56  
57  
58  
59  
60

- 1  
2  
3 Splenic trauma and overwhelming postsplenectomy infection. *Br J Surg*.  
4 1987;74:343–5.  
5  
6 30. Lynch AM, Kapila R. Overwhelming postsplenectomy infection. *Infect Dis Clin*  
7 *North Am*. 1996;10:693–707.  
8  
9 31. Lai SW, Muo CH, Liao KF, Sung FC, Chen PC. Risk of acute pancreatitis in type  
10 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort  
11 study in Taiwan. *Am J Gastroenterol*. 2011;106:1697–704.  
12  
13 32. Lai HC, Lin CC, Cheng KS, Kao JT, Chou JW, Peng CY, et al. Increased  
14 incidence of gastrointestinal cancers among patients with pyogenic liver abscess: a  
15 population-based cohort study. *Gastroenterology*. 2014;146:129–37 e1.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Table 1. Baseline characteristics between splenectomy group and non-splenectomy group**

	Splenectomy				<i>P</i> value*
	No		Yes		
	N	%	n	%	
Sex					0.88
Female	20431	38.9	5128	38.9	
Male	32033	61.1	8065	61.1	
Age group (years)					0.98
20–39	13415	25.6	3364	25.5	
40–64	24112	46.0	6062	46.0	
65–84	14937	28.5	3767	28.6	
Age (years), mean (standard deviation) <sup>†</sup>	52.5	17.2	52.8	17.2	0.05
Follow-up period (years), mean (standard deviation) <sup>†</sup>	5.75	3.32	4.37	3.44	< 0.001
Baseline comorbidities					
Alcohol-related diseases	1787	3.41	452	3.43	0.91
Cancers	7677	14.6	1962	14.9	0.49
Chronic kidney diseases	1068	2.04	270	2.05	0.94
Chronic liver diseases	7791	14.9	1971	14.9	0.80
Chronic obstructive pulmonary diseases	2002	3.82	507	3.84	0.89
Diabetes mellitus	7856	15.0	1983	15.0	0.87

Data are presented as the number of subjects in each group, with percentages given in parentheses, or mean with standard deviation given in parentheses.

\*Chi-square test, and <sup>†</sup>t-test comparing subjects with and without splenectomy.

**Table 2. Incidence density of empyema estimated by sex, age, and follow-up period between splenectomy group and non-splenectomy group**

	Non-splenectomy				Splenectomy				IRR <sup>#</sup>	(95% CI)
	N	Cases	Person- years	Incidence <sup>†</sup>	N	Cases	Person- years	Incidence <sup>†</sup>		
All	52464	1042	301484	3.46	13193	510	57622	8.85	2.56 (2.44,2.69)	
Sex										
Female	20431	317	119441	2.65	5128	159	23004	6.91	2.60 (2.40, 2.82)	
Male	32033	725	182042	3.98	8065	351	34618	10.1	2.55 (2.39, 2.71)	
Age group (years)										
20–39	13415	57	84004	0.68	3364	65	19700	3.30	4.86 (4.39, 5.39)	
40–64	24112	354	140554	2.52	6062	224	26423	8.48	3.37 (3.13, 3.62)	
65-84	14937	631	76925	8.20	3767	221	11499	19.2	2.34 (2.14, 2.56)	
Follow-up period (years)										
< 5	52464	720	206010	3.49	13193	416	41545	10.0	2.87 (2.73, 3.01)	
≥ 5	28456	322	95474	3.37	5052	94	16077	5.85	1.73 (1.60, 1.88)	

<sup>†</sup> Incidence rate: per 1,000 person-years.

<sup>#</sup>IRR (incidence rate ratio): splenectomy vs. non-splenectomy (95% CI)

**Table 3. Adjusted hazard ratio and 95% confidence interval of empyema associated with splenectomy and other comorbidities**

Variable	Crude	Adjusted <sup>†</sup>
	HR (95%CI)	HR (95%CI)
Sex (male vs. female)	1.48 (1.33, 1.65)	1.51 (1.35, 1.68)
Age (per one year)	1.05 (1.04, 1.05)	1.05 (1.05, 1.06)
Baseline comorbidities (yes vs. no)		
<b>Splenectomy</b>	<b>2.52 (2.26, 2.80)</b>	<b>2.89 (2.60, 3.22)</b>
Alcohol-related diseases	1.61 (1.28, 2.03)	2.25 (1.76, 2.86)
Cancers	2.60 (2.31, 2.92)	1.92 (1.71, 2.17)
Chronic kidney diseases	3.04 (2.40, 3.85)	2.13 (1.67, 2.70)
Chronic liver diseases	2.07 (1.84, 2.34)	1.90 (1.68, 2.14)
Chronic obstructive pulmonary diseases	3.95 (3.37, 4.64)	1.75 (1.48, 2.07)
Diabetes mellitus	2.80 (2.51, 3.13)	1.85 (1.65, 2.07)

Only those found to be significant in the univariable analysis were further examined in the multivariable analysis.

<sup>†</sup>Additionally adjusted for age, sex, alcohol-related diseases, cancers, chronic kidney diseases, chronic liver diseases, chronic obstructive pulmonary diseases, and diabetes mellitus

**Table 4. Cox proportional hazard regression analysis for risk of empyema stratified by splenectomy and comorbidities**

Variable		Event	Incidence <sup>†</sup>	Adjusted HR <sup>#</sup> (95% CI)
Splenectomy	Any comorbidity*			
No	No	299	1.49	1(Reference)
No	Yes	743	7.34	3.64(3.18, 4.17)
Yes	No	230	5.75	4.52(3.80, 5.37)
Yes	Yes	280	15.9	8.23(6.98, 9.70)

<sup>†</sup> Incidence rate: per 1,000 person-years

<sup>#</sup> Adjusted for sex and age

\*Comorbidities including alcohol-related diseases, cancers, chronic kidney diseases, chronic liver diseases, chronic obstructive pulmonary diseases, and diabetes mellitus  
95% CI: 95% confidence interval

# BMJ Open

## Population-based cohort study examining the association between splenectomy and empyema in adults in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015101.R1
Article Type:	Research
Date Submitted by the Author:	07-Mar-2017
Complete List of Authors:	Lin, Hsien-Feng; China Medical University Hospital, ; Liao, Kuan-Fu Chang, Ching-Mei Lin, Cheng-Li Lai, Shih-Wei; China Medical University Hospital, Department of Family Medicine
<b>Primary Subject Heading</b>:	General practice / Family practice
Secondary Subject Heading:	Gastroenterology and hepatology
Keywords:	empyema, splenectomy, Taiwan National Health Insurance Program

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Type of manuscript: Original article

**New manuscript title: Population-based cohort study examining the association between splenectomy and empyema in adults in Taiwan**

□ Running head: splenectomy and empyema

• Authors' full names:

Hsien-Feng Lin MD and MS<sup>1,2</sup>; Kuan-Fu Liao MD and MS<sup>3,4,5</sup>; Ching-Mei Chang RN and MSN<sup>6</sup>; Cheng-Li Lin MS<sup>7,8</sup>; Shih-Wei Lai MD<sup>2,7</sup>

• (The first three authors contributed equally to this study)

• <sup>1</sup>School of Chinese Medicine, <sup>5</sup>Graduate Institute of Integrated Medicine, and <sup>7</sup>College of Medicine, China Medical University, Taichung, Taiwan.

• <sup>3</sup>Department of Internal Medicine, Taichung Tzu Chi General Hospital, Taichung, Taiwan

• <sup>4</sup>College of Medicine, Tzu Chi University, Hualien, Taiwan

• <sup>2</sup>Department of Family Medicine and <sup>8</sup>Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan.

• <sup>6</sup>Assistant Professor and Deputy Director, Department of Nursing, Tungs' Taichung Metro Harbor Hospital, Taichung<sup>7</sup>, Taiwan

• Corresponding author: Shih-Wei Lai, Department of Family Medicine, China Medical University Hospital, No 2, Yuh-Der Road, Taichung City, 404, Taiwan

Phone: 886-4-2205-2121; Fax: 886-4-2203-3986

E-mail: wei@mail.cmuh.org.tw

## ABSTRACT

**Objectives.** Little is known about the risk of empyema in patients with splenectomy. We investigate the relationship between splenectomy and empyema in Taiwan.

**Methods.** We conducted a population-based cohort analysis using the hospitalization dataset of the Taiwan National Health Insurance Program. There were 13193 subjects aged 20 to 84 years who were newly diagnosed with splenectomy in 2000 to 2010 as the splenectomy group and 52464 randomly selected subjects without splenectomy as the non-splenectomy group. Both groups were matched by sex, age, comorbidities, and hospitalization year of performing splenectomy. The incidence of empyema at the end of 2011 was calculated. The multivariable Cox proportional hazards regression model was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for empyema associated with splenectomy and other comorbidities. **Results.** The overall incidence rate of empyema was 2.56-fold higher in the splenectomy group than that in the non-splenectomy group (8.85 vs. 3.46 per 1,000 person-years, 95% CI 2.44, 2.69). The Kaplan-Meier model revealed that the splenectomy group had a higher cumulative incidence of pleural empyema than the non-splenectomy group (6.99% vs. 3.37% at the end of follow-up;  $P < 0.001$ ). After adjusted for confounders, the adjusted HR of empyema was 2.89 in subjects with splenectomy (95%CI 2.60, 3.22), compared with subjects without splenectomy. In further analysis, in the absence of comorbidities studied, the HR was 4.52 for those with splenectomy alone (95% CI=3.80, 5.37). **Conclusions.** Patients with splenectomy are associated with 2.89-fold increased risk of empyema. In the absence of comorbidities, the risk remains high.

**Keywords:** empyema; splenectomy; Taiwan National Health Insurance Program

### Strengths and limitations of this study.

1. This is the first original study on the association between splenectomy and empyema.
2. We used a hospitalization dataset with a large sample size and great statistical power.
3. Some traditional behavior risk factors including alcohol consumption and cigarette smoking were not recorded due to the inherent limitation of this insurance database.
4. The underlying causes for splenectomy in this present study were not recorded due to the inherent limitation of this insurance database.
5. Such a study design does not permit to conclude a substantial causality.

## INTRODUCTION

Empyema is a suppurative infection of the pleural space. The creation of empyema can be divided into two distinct mechanisms. Empyema occurs most commonly after pneumonia, with direct spread of organisms into the pleural space. This occurs in approximately 1% to 5% of pneumonias.<sup>1,2</sup> The other mechanism occurs after surgery, most commonly of the thorax, esophagus, lung or heart. Empyema is an ancient disease that continues to be an important clinical problem nowadays. Despite the centuries of learned experience, the appearance of antibiotics and the use of different pneumococcal vaccines, empyema remains the most common complication of pneumonia and an important cause of morbidity worldwide.<sup>3</sup> The incidence of pleural infections diminished significantly during the first half of the 20th century because of the development of antibiotics. However, this trend changed at the end of the 20th century and, since the decade of the 1990s the incidence of empyema has tended to be increasing worldwide.

The human spleen mainly serves an immune function against invading microorganisms.<sup>4,5</sup> The immunologic and hematologic functions of the spleen in humans are well known. Specifically, the spleen protects against infections mediated by innate and adaptive immunity.<sup>6,7</sup> Patients with splenectomy are more likely than those without splenectomy to suffer severe life-threatening infections. Splenectomy is associated with increased risk of some diseases, including pulmonary tuberculosis, type 2 diabetes mellitus, pyogenic liver abscess, renal and perinephric abscesses, and acute pancreatitis,<sup>8-12</sup> but empyema has not yet been studied.

Despite the incidence of empyema has tended to be increasing worldwide, no study has evaluated the association between splenectomy and empyema. We rationally hypothesize an association between splenectomy and empyema due to the immunocompromised condition caused by splenectomy, which can further increase



1  
2  
3 the risk of microorganism invasion of the pleural space. However, published literature  
4 from epidemiological studies on this issue is scarce. Given that splenectomy is  
5 associated with overwhelming postsplenectomy infections and empyema carries a  
6 potential fatality, exploring the risk of empyema in patients with splenectomy may  
7 have significant clinical and public health implications. Therefore, to explore whether  
8 there is an association between splenectomy and empyema, we conducted a  
9 nationwide cohort study using the hospitalization dataset of the Taiwan National  
10 Health Insurance Program.  
11  
12  
13  
14  
15  
16  
17  
18  
19

## 20 **METHODS**

### 21 **Study design and data source**

22  
23  
24  
25 Taiwan is an independent country with more than 23 million people. We conducted  
26 a population-based cohort study using insurance claim data from the Taiwan National  
27 Health Insurance Program which covers 99% of the whole Taiwan population since  
28 1995.<sup>13</sup> The details of the insurance program have been well written in previous  
29 studies.<sup>14-17</sup> The study was approved by the Institutional Review Board of China  
30 Medical University and Hospital in Taiwan (CMUH-104-REC2-115).  
31  
32  
33  
34  
35  
36  
37

### 38 **Sampled Participants**

39  
40 Using the hospitalization dataset of the Taiwan National Health Insurance Program,  
41 all hospitalized subjects aged 20 to 84 who performed splenectomy (International  
42 Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9 procedure  
43 code 41.5) between January 1, 2000 and December 31, 2010, were identified as the  
44 splenectomy group. The date for undergoing splenectomy was defined as the index  
45 date. For each subject with splenectomy, 4 subjects without splenectomy were  
46 randomly selected from the same database as the non-splenectomy group. Both  
47 groups were matched by sex, age (every 5-year span), comorbidities, and the  
48 hospitalization year of performing splenectomy. To reduce the biased results, subjects  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 who had an empyema diagnosis (ICD-9 codes 510, 511.1, 511.8, and 511.9) within  
4 one month after performing splenectomy were excluded from the study.  
5  
6

### 7 8 **Outcome and Comorbidities**

9  
10 The main outcome was a new diagnosis of empyema based on hospital discharge  
11 registries during the follow-up period. Each subject was monitored from the index  
12 date until being diagnosed with empyema, or being censored because of loss to  
13 follow-up, death, or withdrawal from insurance, or to the end of December 31, 2011.  
14  
15 Comorbidities investigated in the study were included as follows: alcohol-related  
16 disease, cancers, chronic kidney disease, chronic liver disease (including cirrhosis,  
17 alcoholic liver damage, hepatitis B, hepatitis C, and other chronic hepatitis), chronic  
18 obstructive pulmonary disease, and diabetes mellitus. All comorbidities were  
19 diagnosed with ICD-9 codes, which have been well assessed in previous studies.<sup>18-28</sup>  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 30 **Statistical analysis**

31  
32 The differences between sex, age, and comorbidities between the splenectomy group  
33 and the non-splenectomy group were compared by using the Chi-square test for  
34 categorical variables, and *t*-test for continuous variables. Follow-up time  
35  
36 (person-years) was used to estimate the incidence rate and incidence rate ratio (IRR)  
37  
38 with 95% confidence interval (CI) of splenectomy group to non-splenectomy group  
39  
40 using Poisson regression, by sex, age, and follow-up period. The multivariable Cox  
41  
42 proportional hazards regression model was used to estimate the hazard ratio (HR)  
43  
44 with 95% confidence interval (CI) of empyema associated with splenectomy and  
45  
46 other comorbidities after simultaneously adjusted for variables found to be significant  
47  
48 in the univariable Cox proportion hazard regression model. The proportional hazard  
49  
50 model assumption was examined by using a test of scaled Schoenfeld residuals. In the  
51  
52 model evaluating empyema risk throughout the overall follow-up period, results of the  
53  
54 test revealed a significant relationship between Schoenfeld residuals for splenectomy  
55  
56  
57  
58  
59  
60

1  
2  
3 and follow-up time, suggesting the proportionality assumption was violated ( $P$  value  
4 < 0.001). In the subsequent analysis, we stratified the follow-up period to deal with  
5  
6 the violation of proportional hazard assumption (Please see Table 2). All statistical  
7  
8 analyses were performed using SAS 9.2 (SAS Institute, Cary, North Carolina, USA).  
9  
10 Two-tailed  $P < 0.05$  was considered statistically significant.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

### Baseline information of the study population

Table 1 discloses the baseline information of the study population. There were 13193 subjects with splenectomy and 52464 subjects without splenectomy during the study period, with similar distributions in sex and age. The mean ages (mean  $\pm$  standard deviation) were  $52.8 \pm 17.2$  years in the splenectomy group and  $52.5 \pm 17.2$  years in the non-splenectomy group (*t* test,  $P = 0.05$ ). The mean follow-up periods (mean  $\pm$  standard deviation) were  $4.37 \pm 3.44$  years in the splenectomy group and  $5.75 \pm 3.32$  years in the non-splenectomy group (*t* test,  $P < 0.001$ ). There was no significant difference in the prevalence of comorbidities studied between the splenectomy group and the non-splenectomy group (Chi-square test,  $P > 0.05$  for all).

### Incidence of empyema stratified by sex, age, and follow-up period

Table 2 discloses the incidence rates of empyema. At the end of the cohort study, the overall incidence rate of empyema was 2.56-fold higher in the splenectomy group than that in the non-splenectomy group (8.85 vs. 3.46 per 1,000 person-years, 95% CI 2.44, 2.69). The incidence rates of empyema, as stratified by sex, age, and follow-up period, were all higher in the splenectomy group than those in the non-splenectomy group. The incidence rates of empyema increased with age in both groups, with the highest in the splenectomy group aged 65 to 84 years (19.2 per 1,000 person-years). Stratified analysis by follow-up period disclosed that the incidence rates of empyema decreased with the follow-up time in both groups. The risk of empyema in the splenectomy group was significantly higher in the first 5 years of follow-up (incidence rate ratio 2.87, 95% CI 2.73, 3.01). However, the risk of empyema still existed in the splenectomy group even after 5 years (incidence rate ratio 1.73, 95% CI 1.60, 1.88).

In Figure 1, the Kaplan-Meier model revealed that the splenectomy group had a

1  
2  
3 higher cumulative incidence of pleural empyema than the non-splenectomy group  
4  
5 (6.99% vs. 3.37% at the end of follow-up;  $P < 0.001$ ).  
6  
7  
8  
9

### 10 **Hazard ratio of empyema associated with splenectomy and other comorbidities**

11  
12 Table 3 discloses the HR of empyema associated with splenectomy and other  
13 comorbidities. Variable found to be statistically significant in the univariable model  
14 were further examined in the multivariable model. After adjusted for age, sex,  
15 alcohol-related disease, cancers, chronic kidney disease, chronic liver disease, chronic  
16 obstructive pulmonary disease, and diabetes mellitus, the multivariable Cox  
17 proportional hazards regression model disclosed that the adjusted HR of empyema  
18 was 2.89 in subjects with splenectomy (95% CI 2.60, 3.22), compared with subjects  
19 without splenectomy.  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 **Interaction effect on risk of empyema between splenectomy and other** 30 **comorbidities**

31  
32 Table 4 discloses interaction effect on risk of empyema between splenectomy and  
33 other comorbidities including alcohol-related diseases, cancers, chronic kidney  
34 diseases, chronic liver diseases, chronic obstructive pulmonary diseases, and diabetes  
35 mellitus. As a reference of subjects without splenectomy and without any comorbidity,  
36 the adjusted HR of empyema was 4.52 for subjects with splenectomy alone and  
37 without any comorbidity (95% CI 3.80, 5.37). The HR markedly increased to 8.23 for  
38 those with splenectomy and comorbid with any comorbidity (95% CI 6.98, 9.70). It  
39 means that there is an interaction effect on risk of empyema between splenectomy and  
40 other comorbidities.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

A review by Sinwar found that the duration between splenectomy and onset of overwhelming post-splenectomy infection could range from less than 1 week to more than 20 years.<sup>29</sup> To diminish biased results, we excluded patients who underwent splenectomy within 1 month of empyema diagnosis to ensure that splenectomy truly preceded the onset of empyema. In this population-based cohort study, we noticed that splenectomy was associated with increased hazard ratio of empyema (adjusted HR 2.89). To the best of our knowledge, this is the first population-based cohort study to examine this issue. Some studies have found that splenectomy is associated with increased risk of some diseases. Lai et al. found that the adjusted odds ratio of acute pancreatitis was 2.90 for subjects with splenectomy (95% CI, 1.39–6.05) compared with subjects without splenectomy,<sup>12</sup> the adjusted hazard ratio of renal and perinephric abscesses was 2.24 for the splenectomy group (95% CI, 1.30–3.88) when compared with the non-splenectomy group,<sup>11</sup> the adjusted hazard ratio of pyogenic liver abscess was 3.89 in subjects with splenectomy (95% confidence interval, 3.20–4.72) when compared with subjects without splenectomy,<sup>10</sup> and the odds of pulmonary tuberculosis were 1.91 in patients with splenectomy (95% CI 1.06–3.44) compared with the participants without splenectomy.<sup>8</sup>

Extensive evidence has revealed that the human spleen mainly serves a protective role against invading microorganisms on the basis of bactericidal capacity of lymphoid cells and macrophages and the humoral immune response.<sup>6,30-32</sup> Upon removal of the spleen, normal immune functions, such as phagocytic activities and the humoral immune response, may be significantly changed. Therefore, impaired immune functions after splenectomy may increase the risk of life-threatening infection and empyema.

In our study, the risk of empyema in the splenectomy group was higher in the first

1  
2  
3 5 years of follow-up than after 5 years (incidence rate ratio 2.87 vs 1.72). However,  
4  
5 the risk of empyema still existed in the splenectomy group even after 5 years. These  
6  
7 findings are compatible with previous studies showing that the majority of severe  
8  
9 infections occur within the first 3 years after splenectomy, and, although the risk  
10  
11 declines over time, the risk might last for more than 5 years after splenectomy.<sup>33-35</sup>  
12  
13 The mechanism remains unknown. We speculate that with time, the immune system  
14  
15 could develop ways to compensate or overcome these immune deficits. So the risk of  
16  
17 empyema in the splenectomy group was higher in the first 5 years of follow-up.  
18  
19 Future studies are needed to confirm this hypothesis.  
20  
21

22  
23 In this study, after controlling for potential confounding factors, we also observed  
24  
25 that patients with splenectomy were at increased risk of empyema (adjusted HR 2.89).  
26  
27 The HR seems to be higher than that observed for comorbidities. The HR was not  
28  
29 confounded by comorbidities studied because there was no significant difference in  
30  
31 the prevalence of comorbidities between the splenectomy group and the  
32  
33 non-splenectomy group. It means the increased hazard of empyema in patients with  
34  
35 splenectomy cannot be totally attributable to the effect of comorbidities. Though these  
36  
37 comorbidities were found to be associated with empyema, to minimize their  
38  
39 confounding effects, we made a further analysis, even in absence of any comorbidity,  
40  
41 patients with splenectomy still had a higher hazard of empyema (HR 4.52). These  
42  
43 results indicate that not requiring the presence of comorbidity, splenectomy may have  
44  
45 a unique role on risk of empyema. These findings are compatible with the literature  
46  
47 that patients with splenectomy are not only more prone to suffer severe  
48  
49 life-threatening infection due to the immunocompromised condition caused by  
50  
51 splenectomy<sup>36,37</sup> but also at an increased hazard of developing empyema.  
52  
53  
54

55  
56 Some limitations in the present study deserve discussion. First, some traditional  
57  
58 behavior risk factors including alcohol consumption and cigarette smoking were not  
59

1  
2  
3 recorded due to the inherent limitation of this insurance database. We used  
4  
5 alcohol-related diseases instead of alcohol consumption and chronic obstructive  
6  
7 pulmonary disease instead of cigarette smoking. Second, the underlying causes for  
8  
9 splenectomy in this present study were not recorded due to the inherent limitation of  
10  
11 this insurance database. Splenectomy is commonly performed in certain disorders and  
12  
13 diseases, such as hematological disorders, gastric cancer, or trauma, so these  
14  
15 background conditions might confound the results. Whether the reasons for  
16  
17 splenectomy are associated with empyema cannot be clarified in this study. Third,  
18  
19 Due to the inherent limitation of this insurance database, the underlying causes for  
20  
21 splenectomy were not recorded. The cause of splenectomy could be the cause of the  
22  
23 empyema, for example, splenic abscess. From a view of the good quality of the  
24  
25 Taiwan medical system, it does not need to spend one month to confirm a diagnosis of  
26  
27 empyema from the onset of empyema prodrome. In order to reduce the biased results,  
28  
29 subjects who had an empyema diagnosis within one month after performing  
30  
31 splenectomy were excluded from the study. Therefore, it is less possible that  
32  
33 splenectomy could be the cause of the empyema. Fourth, empyema could correlate  
34  
35 very well with open surgery. However, due to the same limitation, the splenectomized  
36  
37 type was not recorded. We did not know how the patients were splenectomized, open  
38  
39 surgery or laparoscopic surgery. Similarly, we did not know that patients underwent  
40  
41 total splenectomy or partial splenectomy. Fifth, lack of vaccination could correlate  
42  
43 very well with empyema. However, due to the same limitation, we did not know how  
44  
45 many of the splenectomized patients were vaccinated against encapsulated bacteria  
46  
47 (especially *Streptococcus pneumoniae*). We could not investigate whether  
48  
49 pneumococcal vaccination might decrease the risk of empyema among patients with  
50  
51 splenectomy in Taiwan. Sixth, due to the same limitation, causative pathogens were  
52  
53 not recorded. We could not investigate what kind of bacteria would cause the  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 empyema among patients with splenectomy. Lack of such information does not permit  
5  
6 the present study to conclude a substantial causality. Further prospective studies are  
7  
8 needed to confirm our findings.  
9

10 The strength of this study is that this is the first original study on the association  
11  
12 between splenectomy and empyema. Although the underlying mechanism linking  
13  
14 splenectomy and empyema cannot be completely determined, our findings are  
15  
16 clinically important. In addition, we used a hospitalization dataset with a large sample  
17  
18 size and great statistical power. The diagnosis codes of included comorbidities have  
19  
20 been documented in previous studies.<sup>18-28</sup> The study design and statistical methods  
21  
22 are described in detail. Our results were relatively convincing because the  
23  
24 splenectomy group and the non-splenectomy group had similar distributions of  
25  
26 studied comorbidities. Therefore, the confounding effects of these comorbidities on  
27  
28 risk of empyema should be minimal.  
29  
30

31 We conclude that patients with splenectomy are associated with 2.89-fold increased  
32  
33 risk of empyema, particularly comorbid with other conditions, including  
34  
35 alcohol-related diseases, cancers, chronic kidney diseases, chronic liver diseases,  
36  
37 chronic obstructive pulmonary diseases, and diabetes mellitus. Even in the absence of  
38  
39 comorbidities, the risk remains high.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Acknowledgement**

This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW106-TDU-B-212-113004), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037), National Research Program for Biopharmaceuticals (NRPB) Stroke Clinical Trial Consortium (MOST 105-2325-B-039 -003), Tseng-Lien Lin Foundation in Taichung in Taiwan, Taiwan Brain Disease Foundation in Taipei in Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds in Japan. These funding agencies did not influence the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### **Specific author contributions**

Hsien-Feng Lin and Kuan-Fu Liao substantially planned and conducted this study, participated in the data interpretation, and also critically revised the article. Ching-Mei Chang and Cheng-Li Lin conducted the data analysis and critically revised the article.

Shih-Wei Lai substantially planned and conducted this study, contributed to the conception of the article, initiated the draft of the article, and critically revised the article.

### **Conflict of Interest Statement**

The authors disclose no conflicts of interest.

### **Funding statement**

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors

**REFERENCES**

1. Ahmed RA, Marrie TJ, Huang JQ. Thoracic empyema in patients with community-acquired pneumonia. *Am J Med* 2006;119:877-83.
2. Shields T, Locicero J, Ponn R, Rusch V, eds. *General Thoracic Surgery*, 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2005:823.
3. Septimus EJ. Pleural effusion and empyema. In: Mandell GL, Bennet JE, Mandell RD, editors. *Douglas and Bennett's principles and practice of infectious diseases*. Edinburgh: Churchill Livingstone; 2009. pp. 917-24.
4. Spencer RP, Pearson HA. The spleen as a hematological organ. *Semin Nucl Med*. 1975;5:95-102.
5. Trigg ME. Immune function of the spleen. *South Med J*. 1979;72:593-9.
6. Jirillo E, Mastronardi ML, Altamura M, Munno I, Miniello S, Urgesi G, et al. The immunocompromised host: immune alterations in splenectomized patients and clinical implications. *Curr Pharm Des*. 2003;9:1918-23.
7. Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. *Lancet*. 2011;378:86-97.
8. Lai SW, Wang IK, Lin CL, Chen HJ, Liao KF. Splenectomy correlates with increased risk of pulmonary tuberculosis: a case-control study in Taiwan. *Clin Microbiol Infect* 2014;20:764-7.
9. Wu SC, Fu CY, Muo CH, Chang YJ. Splenectomy in trauma patients is associated with an increased risk of postoperative type II diabetes: a nationwide population-based study. *Am J Surg* 2014;208:811-6.
10. Lai SW, Lai HC, Lin CL, Liao KF. Splenectomy Correlates With Increased Risk of Pyogenic Liver Abscess: A Nationwide Cohort Study in Taiwan. *J Epidemiol* 2015;25:561-6.
11. Lai SW, Lin HF, Lin CL, Liao KF. Splenectomy and risk of renal and perinephric abscesses: A population-based cohort study in Taiwan. *Medicine* 2016;95:31(e4438).
12. Lai SW, Lin CL, Liao KF. Splenectomy Correlates With Increased Risk of Acute Pancreatitis: A Case-Control Study in Taiwan. *J Epidemiol* 2016;26:488-92.
13. National Health Insurance Research Database. Taiwan. <http://nhird.nhri.org.tw/en/index.html> [cited in March 1, 2017, English version].
14. Lai SW, Liao KF, Liao CC, Muo CH, Liu CS, Sung FC. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. *Medicine* 2010;89:295-9.
15. Chen HY, Lai SW, Muo CH, Chen PC, Wang IJ. Ethambutol-induced optic neuropathy: a nationwide population-based study from Taiwan. *Br J Ophthalmol*

- 2012;96:1368-71.
16. Yang SP, Muo CH, Wang IK, et al. Risk of type 2 diabetes mellitus in female breast cancer patients treated with morphine: A retrospective population-based time-dependent cohort study. *Diabetes Res Clin Pract* 2015;110:285-90.
  17. Tsai TY, Lin CC, Peng CY, et al. The association between biliary tract inflammation and risk of digestive system cancers: A population-based cohort study. *Medicine* 2016;95:31(e4427).
  18. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. *Am J Gastroenterol* 2012;107:46-52.
  19. Liao KF, Lin CL, Lai SW, Chen WC. Zolpidem Use Associated With Increased Risk of Pyogenic Liver Abscess: A Case-Control Study in Taiwan. *Medicine* 2015;94:32(e1302).
  20. Wong TS, Liao KF, Lin CM, Lin CL, Chen WC, Lai SW. Chronic Pancreatitis Correlates With Increased Risk of Cerebrovascular Disease: A Retrospective Population-Based Cohort Study in Taiwan. *Medicine* 2016;95:15(e3266).
  21. Liao KF, Lai SW, Lin CL, Chien SH. Appendectomy correlates with increased risk of pyogenic liver abscess: A population-based cohort study in Taiwan. *Medicine* 2016;95:26(e4015).
  22. Cheng KC, Lin WY, Liu CS, Lin CC, Lai HC, Lai SW. Association of different types of liver disease with demographic and clinical factors. *BioMedicine-Taiwan* 2016;6:16-22.
  23. Liao KF, Cheng KC, Lin CL, Lai SW. Etodolac and the risk of acute pancreatitis. *BioMedicine-Taiwan* 2017;7:25-9.
  24. Shen ML, Liao KF, Tsai SM, Lin CL, Lai SW. Herpes zoster correlates with pyogenic liver abscesses in Taiwan. *BioMedicine-Taiwan* 2016;6:24-9.
  25. Lai SW. Risks and benefits of zolpidem use in Taiwan: a narrative review. *BioMedicine-Taiwan* 2016;6:9-11.
  26. Lin HF, Lai SW, Lin WY, Liu CS, Lin CC, Chang CM. Prevalence and factors of elevated alanine aminotransferase in central Taiwan - a retrospective study. *BioMedicine-Taiwan* 2016;6:25-30.
  27. Lai SW, Muo CH, Liao KF, Sung FC, Chen PC. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. *Am J Gastroenterol*. 2011;106:1697-704.
  28. Lai HC, Lin CC, Cheng KS, Kao JT, Chou JW, Peng CY, et al. Increased incidence of gastrointestinal cancers among patients with pyogenic liver abscess: a population-based cohort study. *Gastroenterology*. 2014;146:129-37 e1.
  29. Sinwar PD. Overwhelming post splenectomy infection syndrome—review study.

- 1  
2  
3 Int J Surg. 2014;12:1314–6.  
4  
5 30. Eibl M. Immunological consequences of splenectomy. Prog Pediatr Surg.  
6 1985;18:139–45.  
7  
8 31. Van Rooijen N. The humoral immune response in the spleen. Res Immunol.  
9 1991;142:328–30.  
10  
11 32. Altamura M, Caradonna L, Amati L, Pellegrino NM, Urgesi G, Miniello S.  
12 Splenectomy and sepsis: the role of the spleen in the immune-mediated bacterial  
13 clearance. Immunopharmacol Immunotoxicol. 2001;23:153–61.  
14  
15 33. Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among  
16 post-splenectomy patients. J Infect. 2001;43:182–6.  
17  
18 34. Kyaw MH, Holmes EM, Toolis F, Wayne B, Chalmers J, Jones IG, et al.  
19 Evaluation of severe infection and survival after splenectomy. Am J Med.  
20 2006;119:276 e1–7.  
21  
22 35. Dendle C, Sundararajan V, Spelman T, Jolley D, Woolley I. Splenectomy  
23 sequelae: an analysis of infectious outcomes among adults in Victoria. Med J Aust.  
24 2012;196:582–6.  
25  
26 36. Di Cataldo A, Puleo S, Li Destri G, Racalbuto A, Trombatore G, Latteri F, et al.  
27 Splenic trauma and overwhelming postsplenectomy infection. Br J Surg.  
28 1987;74:343–5.  
29  
30 37. Lynch AM, Kapila R. Overwhelming postsplenectomy infection. Infect Dis Clin  
31 North Am. 1996;10:693–707.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1. Baseline characteristics between splenectomy group and non-splenectomy group**

Variable	Splenectomy				<i>P</i> value*
	No		Yes		
	N	%	n	%	
Sex					0.88
Female	20431	38.9	5128	38.9	
Male	32033	61.1	8065	61.1	
Age group (years)					0.98
20–39	13415	25.6	3364	25.5	
40–64	24112	46.0	6062	46.0	
65–84	14937	28.5	3767	28.6	
Age (years), mean (standard deviation) <sup>†</sup>	52.5	(17.2)	52.8	(17.2)	0.05
Follow-up period (years), mean (standard deviation) <sup>†</sup>	5.75	(3.32)	4.37	(3.44)	< 0.001
Baseline comorbidities					
Alcohol-related disease	1787	3.41	452	3.43	0.91
Cancers	7677	14.6	1962	14.9	0.49
Chronic kidney disease	1068	2.04	270	2.05	0.94
Chronic liver disease	7791	14.9	1971	14.9	0.80
Chronic obstructive pulmonary disease	2002	3.82	507	3.84	0.89
Diabetes mellitus	7856	15.0	1983	15.0	0.87

Data are presented as the number of subjects in each group, with percentages given in parentheses, or mean with standard deviation given in parentheses.

\*Chi-square test, and <sup>†</sup>*t*-test comparing subjects with and without splenectomy.

**Table 2. Incidence density of empyema estimated by sex, age, and follow-up period between splenectomy group and non-splenectomy group**

Variable	Non-splenectomy				Splenectomy				IRR <sup>#</sup> (95% CI)
	N	Cases	Person-years	Incidence <sup>†</sup>	N	Cases	Person-years	Incidence <sup>†</sup>	
All	52464	1042	301484	3.46	13193	510	57622	8.85	2.56 (2.44, 2.69)
Sex									
Female	20431	317	119441	2.65	5128	159	23004	6.91	2.60 (2.40, 2.82)
Male	32033	725	182042	3.98	8065	351	34618	10.1	2.55 (2.39, 2.71)
Age group (years)									
20–39	13415	57	84004	0.68	3364	65	19700	3.30	4.86 (4.39, 5.39)
40–64	24112	354	140554	2.52	6062	224	26423	8.48	3.37 (3.13, 3.62)
65–84	14937	631	76925	8.20	3767	221	11499	19.2	2.34 (2.14, 2.56)
Follow-up period (years)									
< 5	52464	720	206010	3.49	13193	416	41545	10.0	2.87 (2.73, 3.01)
≥ 5	28456	322	95474	3.37	5052	94	16077	5.85	1.73 (1.60, 1.88)

<sup>†</sup> Incidence rate: per 1,000 person-years.

<sup>#</sup>IRR (incidence rate ratio): splenectomy vs. non-splenectomy (95% CI)

**Table 3. Adjusted hazard ratio and 95% confidence interval of empyema associated with splenectomy and other comorbidities**

Variable	Crude	Adjusted <sup>†</sup>
	HR (95%CI)	HR (95%CI)
Sex (male vs. female)	1.48 (1.33, 1.65)	1.51 (1.35, 1.68)
Age (per one year)	1.05 (1.04, 1.05)	1.05 (1.05, 1.06)
Baseline comorbidities (yes vs. no)		
<b>Splenectomy</b>	<b>2.52 (2.26, 2.80)</b>	<b>2.89 (2.60, 3.22)</b>
Alcohol-related disease	1.61 (1.28, 2.03)	2.25 (1.76, 2.86)
Cancers	2.60 (2.31, 2.92)	1.92 (1.71, 2.17)
Chronic kidney disease	3.04 (2.40, 3.85)	2.13 (1.67, 2.70)
Chronic liver disease	2.07 (1.84, 2.34)	1.90 (1.68, 2.14)
Chronic obstructive pulmonary disease	3.95 (3.37, 4.64)	1.75 (1.48, 2.07)
Diabetes mellitus	2.80 (2.51, 3.13)	1.85 (1.65, 2.07)

<sup>†</sup>Variable found to be statistically significant in the univariable model were further examined in the multivariable model.

Adjusted for age, sex, alcohol-related disease, cancers, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease, and diabetes mellitus



**Table 4. Cox proportional hazard regression analysis for risk of empyema stratified by splenectomy and comorbidities**

Variable		Event	Incidence <sup>†</sup>	Adjusted HR <sup>#</sup> (95% CI)
Splenectomy	Any comorbidity*			
No	No	299	1.49	1(Reference)
No	Yes	743	7.34	3.64(3.18, 4.17)
Yes	No	230	5.75	4.52(3.80, 5.37)
Yes	Yes	280	15.9	8.23(6.98, 9.70)

<sup>†</sup> Incidence rate: per 1,000 person-years

<sup>#</sup> Adjusted for sex and age


\*Comorbidities including alcohol-related disease, cancers, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease, and diabetes mellitus

95% CI: 95% confidence interval

1  
2  
3  
4 Fig 1: Kaplan-Meier model revealed that the splenectomy group had a higher  
5  
6 cumulative incidence of pleural empyema than the non-splenectomy group  
7  
8 (6.99% vs. 3.37% at the end of follow-up;  $P < 0.001$ )  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



190x107mm (300 x 300 DPI)

review only

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
<b>Title and abstract</b>	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	
<b>Introduction</b>				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3	
Objectives	3	State specific objectives, including any prespecified hypotheses	3,4	
<b>Methods</b>				
Study design	4	Present key elements of study design early in the paper	4	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	4	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5	
Bias	9	Describe any efforts to address potential sources of bias	4,5	
Study size	10	Explain how the study size was arrived at	4	

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5
		(b) Describe any methods used to examine subgroups and interactions	5
		(c) Explain how missing data were addressed	5
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	5
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
	(e) Describe any sensitivity analyses	6	
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	7,8
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8
		(b) Report category boundaries when continuous variables were categorized	8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	8

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10-12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

# BMJ Open

## Population-based cohort study examining the association between splenectomy and empyema in adults in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015101.R2
Article Type:	Research
Date Submitted by the Author:	11-Apr-2017
Complete List of Authors:	Lin, Hsien-Feng; China Medical University Hospital, ; Liao, Kuan-Fu Chang, Ching-Mei Lin, Cheng-Li Lai, Shih-Wei; China Medical University Hospital, Department of Family Medicine
<b>Primary Subject Heading</b>:	General practice / Family practice
Secondary Subject Heading:	Gastroenterology and hepatology
Keywords:	empyema, splenectomy, Taiwan National Health Insurance Program

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Type of manuscript: Original article

**Manuscript title: Population-based cohort study examining the association between splenectomy and empyema in adults in Taiwan**

□ Running head: splenectomy and empyema

• Authors' full names:

Hsien-Feng Lin MD and MS<sup>1,2</sup>; Kuan-Fu Liao MD and MS<sup>3,4,5</sup>; Ching-Mei Chang RN and MSN<sup>6</sup>; Cheng-Li Lin MS<sup>7,8</sup>; Shih-Wei Lai MD<sup>2,7</sup>

• (The first three authors contributed equally to this study)

• <sup>1</sup>School of Chinese Medicine, <sup>5</sup>Graduate Institute of Integrated Medicine, and <sup>7</sup>College of Medicine, China Medical University, Taichung, Taiwan.

• <sup>3</sup>Department of Internal Medicine, Taichung Tzu Chi General Hospital, Taichung, Taiwan

• <sup>4</sup>College of Medicine, Tzu Chi University, Hualien, Taiwan

• <sup>2</sup>Department of Family Medicine and <sup>8</sup>Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan.

• <sup>6</sup>Assistant Professor and Deputy Director, Department of Nursing, Tungs' Taichung Metro Harbor Hospital, Taichung, Taiwan

• Corresponding author: Shih-Wei Lai, Department of Family Medicine, China Medical University Hospital, No 2, Yuh-Der Road, Taichung City, 404, Taiwan

Phone: 886-4-2205-2121; Fax: 886-4-2203-3986

E-mail: wei@mail.cmuh.org.tw



## ABSTRACT

**Objectives.** Little is known about the risk of empyema in patients with splenectomy. We investigate the relationship between splenectomy and empyema in Taiwan.

**Methods.** We conducted a population-based cohort analysis using the hospitalization dataset of the Taiwan National Health Insurance Program. There were 13193 subjects aged 20 to 84 years who were newly diagnosed with splenectomy in 2000 to 2010 as the splenectomy group and 52464 randomly selected subjects without splenectomy as the non-splenectomy group. Both groups were matched by sex, age, comorbidities, and hospitalization year of undergoing splenectomy. The incidence of empyema at the end of 2011 was calculated. The multivariable Cox proportional hazards regression model was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for empyema associated with splenectomy and other comorbidities. **Results.** The overall incidence rate of empyema was 2.56-fold higher in the splenectomy group than that in the non-splenectomy group (8.85 vs. 3.46 per 1,000 person-years, 95% CI 2.44, 2.69). The Kaplan-Meier model revealed that the splenectomy group had a higher cumulative incidence of empyema than the non-splenectomy group (6.99% vs. 3.37% at the end of follow-up). After adjusted for confounders, the adjusted HR of empyema was 2.89 in subjects with splenectomy (95%CI 2.60, 3.22), compared with subjects without splenectomy. In further analysis, in the absence of comorbidities studied, the HR was 4.52 for those with splenectomy alone (95% CI=3.80, 5.37). **Conclusions.** Patients with splenectomy are associated with 2.89-fold increased risk of empyema. In the absence of comorbidities, the risk remains high. The incidence rate ratio between splenectomy and non-splenectomy from 2.87 reduced to 1.73 after 5 years, but the risk of empyema still existed in the splenectomy group. Future studies are needed to confirm that if the study had an even longer follow up, this average would have gone down further.

**Keywords:** empyema; splenectomy; Taiwan National Health Insurance Program

### Strengths and limitations of this study.

1. This is the first original study on the association between splenectomy and empyema.
2. We used a hospitalization dataset with a large sample size and great statistical power.
3. Some traditional behavior risk factors including alcohol consumption and cigarette smoking were not recorded due to the inherent limitation of this insurance database.
4. The underlying causes for splenectomy in this present study were not recorded

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

due to the inherent limitation of this insurance database.

- 5. Such a study design does not permit to conclude a substantial causality.

For peer review only

## INTRODUCTION

Empyema is a suppurative infection of the pleural space. The creation of empyema can be divided into two distinct mechanisms. Empyema occurs most commonly after pneumonia, with direct spread of organisms into the pleural space. This occurs in approximately 1% to 5% of pneumonias.<sup>1,2</sup> The other mechanism occurs after surgery, most commonly of the thorax, esophagus, lung or heart. Empyema is an ancient disease that continues to be an important clinical problem nowadays. Despite the centuries of learned experience, the appearance of antibiotics and the use of different pneumococcal vaccines, empyema remains the most common complication of pneumonia and an important cause of morbidity worldwide.<sup>3</sup> The incidence of pleural infections diminished significantly during the first half of the 20th century because of the development of antibiotics. However, this trend changed at the end of the 20th century and, since the decade of the 1990s the incidence of empyema has tended to be increasing worldwide.

The human spleen mainly serves an immune function against invading microorganisms.<sup>4,5</sup> The immunologic and hematologic functions of the spleen in humans are well known. Specifically, the spleen protects against infections mediated by innate and adaptive immunity.<sup>6,7</sup> Patients with splenectomy are more likely than those without splenectomy to suffer severe life-threatening infections. Splenectomy is associated with increased risk of some diseases, including pulmonary tuberculosis, type 2 diabetes mellitus, pyogenic liver abscess, renal and perinephric abscesses, and acute pancreatitis,<sup>8-12</sup> but empyema has not yet been studied.

Despite the incidence of empyema has tended to be increasing worldwide, no study has evaluated the association between splenectomy and empyema. We rationally hypothesize an association between splenectomy and empyema due to the immunocompromised condition caused by splenectomy, which can further increase

1  
2  
3 the risk of microorganism invasion of the pleural space. However, published literature  
4 from epidemiological studies on this issue is scarce. Given that splenectomy is  
5 associated with overwhelming postsplenectomy infections and empyema carries a  
6 potential fatality, exploring the risk of empyema in patients with splenectomy may  
7 have significant clinical and public health implications. Therefore, to explore whether  
8 there is an association between splenectomy and empyema, we conducted a  
9 nationwide cohort study using the hospitalization dataset of the Taiwan National  
10 Health Insurance Program.  
11  
12  
13  
14  
15  
16  
17  
18  
19

## 20 **METHODS**

### 21 **Study design and data source**

22  
23  
24  
25 Taiwan is an independent country with more than 23 million people. We conducted  
26 a population-based cohort study using insurance claim data from the Taiwan National  
27 Health Insurance Program which covers 99% of the whole Taiwan population since  
28 1995.<sup>13</sup> The details of the insurance program have been well written in previous  
29 studies.<sup>14-17</sup> The study was approved by the Institutional Review Board of China  
30 Medical University and Hospital in Taiwan (CMUH-104-REC2-115).  
31  
32  
33  
34  
35  
36  
37

### 38 **Sampled Participants**

39  
40 Using the hospitalization dataset of the Taiwan National Health Insurance Program,  
41 all hospitalized subjects aged 20 to 84 who underwent splenectomy (International  
42 Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9 procedure  
43 code 41.5) between January 1, 2000 and December 31, 2010, were identified as the  
44 splenectomy group. The date for undergoing splenectomy was defined as the index  
45 date. For each subject with splenectomy, 4 subjects without splenectomy were  
46 randomly selected from the same database as the non-splenectomy group. Both  
47 groups were matched by sex, age (every 5-year span), comorbidities, and the  
48 hospitalization year of undergoing splenectomy. To reduce the biased results, subjects  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 who had an empyema diagnosis (ICD-9 codes 510, 511.1, 511.8, and 511.9) within  
4 one month after undergoing splenectomy were excluded from the study.  
5  
6

### 7 8 **Outcome and Comorbidities**

9  
10 The main outcome was a new diagnosis of empyema based on hospital discharge  
11 registries during the follow-up period. Each subject was monitored from the index  
12 date until being diagnosed with empyema, or being censored because of loss to  
13 follow-up, death, or withdrawal from insurance, or to the end of December 31, 2011.  
14  
15 Comorbidities investigated in the study were included as follows: alcohol-related  
16 disease, cancers, chronic kidney disease, chronic liver disease (including cirrhosis,  
17 alcoholic liver damage, hepatitis B, hepatitis C, and other chronic hepatitis), chronic  
18 obstructive pulmonary disease, and diabetes mellitus. All comorbidities were  
19 diagnosed with ICD-9 codes, which have been well assessed in previous studies.<sup>18-28</sup>  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 30 **Statistical analysis**

31  
32 The differences between sex, age, and comorbidities between the splenectomy group  
33 and the non-splenectomy group were compared by using the Chi-square test for  
34 categorical variables, and *t*-test for continuous variables. Follow-up time  
35 (person-years) was used to estimate the incidence rate and incidence rate ratio (IRR)  
36 with 95% confidence interval (CI) of splenectomy group to non-splenectomy group  
37 using Poisson regression, by sex, age, and follow-up period. The multivariable Cox  
38 proportional hazards regression model was used to estimate the hazard ratio (HR)  
39 with 95% confidence interval (CI) of empyema associated with splenectomy and  
40 other comorbidities after simultaneously adjusted for variables found to be significant  
41 in the univariable Cox proportion hazard regression model. The proportional hazard  
42 model assumption was examined by using a test of scaled Schoenfeld residuals. In the  
43 model evaluating empyema risk throughout the overall follow-up period, results of the  
44 test revealed a significant relationship between Schoenfeld residuals for splenectomy  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 and follow-up time, suggesting the proportionality assumption was violated ( $P$  value  
4 < 0.001). In the subsequent analysis, we stratified the follow-up period to deal with  
5  
6 the violation of proportional hazard assumption (Please see Table 2). All statistical  
7  
8 analyses were performed using SAS 9.2 (SAS Institute, Cary, North Carolina, USA).  
9  
10  
11  
12 Two-tailed  $P < 0.05$  was considered statistically significant.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## RESULTS

### Baseline information of the study population

Table 1 discloses the baseline information of the study population. There were 13193 subjects with splenectomy and 52464 subjects without splenectomy during the study period, with similar distributions in sex and age. The mean ages (mean  $\pm$  standard deviation) were  $52.8 \pm 17.2$  years in the splenectomy group and  $52.5 \pm 17.2$  years in the non-splenectomy group (*t* test,  $P = 0.05$ ). The mean follow-up periods (mean  $\pm$  standard deviation) were  $4.37 \pm 3.44$  years in the splenectomy group and  $5.75 \pm 3.32$  years in the non-splenectomy group (*t* test,  $P < 0.001$ ). There was no significant difference in the prevalence of comorbidities studied between the splenectomy group and the non-splenectomy group (Chi-square test,  $P > 0.05$  for all).

### Incidence of empyema stratified by sex, age, and follow-up period

Table 2 discloses the incidence rates of empyema. At the end of the cohort study, the overall incidence rate of empyema was 2.56-fold higher in the splenectomy group than that in the non-splenectomy group (8.85 vs. 3.46 per 1,000 person-years, 95% CI 2.44, 2.69). The incidence rates of empyema, as stratified by sex, age, and follow-up period, were all higher in the splenectomy group than those in the non-splenectomy group. The incidence rates of empyema increased with age in both groups, with the highest in the splenectomy group aged 65 to 84 years (19.2 per 1,000 person-years). Stratified analysis by follow-up period disclosed that the incidence rates of empyema decreased with the follow-up time in both groups. The risk of empyema in the splenectomy group was significantly higher in the first 5 years of follow-up (incidence rate ratio 2.87, 95% CI 2.73, 3.01). However, the risk of empyema still existed in the splenectomy group even after 5 years (incidence rate ratio 1.73, 95% CI 1.60, 1.88).

In Figure 1, the Kaplan-Meier model revealed that the splenectomy group had a

1  
2  
3 higher cumulative incidence of pleural empyema than the non-splenectomy group  
4  
5 (6.99% vs. 3.37% at the end of follow-up;  $P < 0.001$ ).  
6  
7  
8  
9

### 10 **Hazard ratio of empyema associated with splenectomy and other comorbidities**

11  
12 Table 3 discloses the HR of empyema associated with splenectomy and other  
13 comorbidities. Variable found to be statistically significant in the univariable model  
14 were further examined in the multivariable model. After adjusted for age, sex,  
15 alcohol-related disease, cancers, chronic kidney disease, chronic liver disease, chronic  
16 obstructive pulmonary disease, and diabetes mellitus, the multivariable Cox  
17 proportional hazards regression model disclosed that the adjusted HR of empyema  
18 was 2.89 in subjects with splenectomy (95% CI 2.60, 3.22), compared with subjects  
19 without splenectomy.  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 **Interaction effect on risk of empyema between splenectomy and other** 30 **comorbidities**

31  
32 Table 4 discloses interaction effect on risk of empyema between splenectomy and  
33 other comorbidities including alcohol-related diseases, cancers, chronic kidney  
34 diseases, chronic liver diseases, chronic obstructive pulmonary diseases, and diabetes  
35 mellitus. As a reference of subjects without splenectomy and without any comorbidity,  
36 the adjusted HR of empyema was 4.52 for subjects with splenectomy alone and  
37 without any comorbidity (95% CI 3.80, 5.37). The HR markedly increased to 8.23 for  
38 those with splenectomy and comorbid with any comorbidity (95% CI 6.98, 9.70). It  
39 means that there is an interaction effect on risk of empyema between splenectomy and  
40 other comorbidities.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## DISCUSSION

A review by Sinwar found that the duration between splenectomy and onset of overwhelming post-splenectomy infection could range from less than 1 week to more than 20 years.<sup>29</sup> To diminish biased results, we excluded patients who underwent splenectomy within 1 month of empyema diagnosis to ensure that splenectomy truly preceded the onset of empyema. In this population-based cohort study, we noticed that splenectomy was associated with increased hazard ratio of empyema (adjusted HR 2.89). To the best of our knowledge, this is the first population-based cohort study to examine this issue. Some studies have found that splenectomy is associated with increased risk of some diseases. Lai et al. found that the adjusted odds ratio of acute pancreatitis was 2.90 for subjects with splenectomy (95% CI, 1.39–6.05) compared with subjects without splenectomy,<sup>12</sup> the adjusted hazard ratio of renal and perinephric abscesses was 2.24 for the splenectomy group (95% CI, 1.30–3.88) when compared with the non-splenectomy group,<sup>11</sup> the adjusted hazard ratio of pyogenic liver abscess was 3.89 in subjects with splenectomy (95% confidence interval, 3.20–4.72) when compared with subjects without splenectomy,<sup>10</sup> and the odds of pulmonary tuberculosis were 1.91 in patients with splenectomy (95% CI 1.06–3.44) compared with the participants without splenectomy.<sup>8</sup>

Extensive evidence has revealed that the human spleen mainly serves a protective role against invading microorganisms on the basis of bactericidal capacity of lymphoid cells and macrophages and the humoral immune response.<sup>6,30-32</sup> Upon removal of the spleen, normal immune functions, such as phagocytic activities and the humoral immune response, may be significantly changed. Therefore, impaired immune functions after splenectomy may increase the risk of life-threatening infection and empyema.

In our study, the risk of empyema in the splenectomy group was higher in the first

1  
2  
3 5 years of follow-up than after 5 years (incidence rate ratio 2.87 vs 1.73). However,  
4  
5 the risk of empyema still existed in the splenectomy group even after 5 years. These  
6  
7 findings are compatible with previous studies showing that the majority of severe  
8  
9 infections occur within the first 3 years after splenectomy, and, although the risk  
10  
11 declines over time, the risk might last for more than 5 years after splenectomy.<sup>33-35</sup>  
12  
13 The mechanism remains unknown. We speculate that with time, the immune system  
14  
15 could develop ways to compensate or overcome these immune deficits. So the risk of  
16  
17 empyema in the splenectomy group was higher in the first 5 years of follow-up.  
18  
19 Future studies are needed to confirm this hypothesis.  
20  
21

22  
23 In this study, after controlling for potential confounding factors, we also observed  
24  
25 that patients with splenectomy were at increased risk of empyema (adjusted HR 2.89).  
26  
27 The phenomenon that would normally be regarded as counter-intuitive and the reason  
28  
29 were unclear. It may be due to some comorbidities which could be potentially related  
30  
31 to empyema should be included in the study, but we lose them. Future studies are  
32  
33 needed to explain this phenomenon. The HR seems to be higher than that observed for  
34  
35 comorbidities. The HR was not confounded by comorbidities studied because there  
36  
37 was no significant difference in the prevalence of comorbidities between the  
38  
39 splenectomy group and the non-splenectomy group. It means the increased hazard of  
40  
41 empyema in patients with splenectomy cannot be totally attributable to the effect of  
42  
43 comorbidities. Though these comorbidities were found to be associated with  
44  
45 empyema, to minimize their confounding effects, we made a further analysis, in  
46  
47 absence of any comorbidity, patients with splenectomy still had a higher hazard of  
48  
49 empyema (HR 4.52). These results indicate that not requiring the presence of  
50  
51 comorbidity, splenectomy may have a unique role on risk of empyema. These findings  
52  
53 are compatible with the literature that patients with splenectomy are not only more  
54  
55 prone to suffer severe life-threatening infection due to the immunocompromised  
56  
57  
58  
59  
60

1  
2  
3 condition caused by splenectomy<sup>36,37</sup> but also at an increased hazard of developing  
4  
5 empyema.  
6

7  
8 Some limitations in the present study deserve discussion. First, some traditional  
9  
10 behavior risk factors including alcohol consumption and cigarette smoking were not  
11  
12 recorded due to the inherent limitation of this insurance database. We used  
13  
14 alcohol-related diseases instead of alcohol consumption and chronic obstructive  
15  
16 pulmonary disease instead of cigarette smoking. Second, the underlying causes for  
17  
18 splenectomy in this present study were not recorded due to the inherent limitation of  
19  
20 this insurance database. Splenectomy is commonly underwent in certain disorders and  
21  
22 diseases, such as hematological disorders, gastric cancer, or trauma, so these  
23  
24 background conditions might confound the results. Whether the reasons for  
25  
26 splenectomy are associated with empyema cannot be clarified in this study. Third,  
27  
28 Due to the inherent limitation of this insurance database, the underlying causes for  
29  
30 splenectomy were not recorded. The cause of splenectomy could be the cause of the  
31  
32 empyema, for example, splenic abscess. From a view of the good quality of the  
33  
34 Taiwan medical system, it does not need to spend one month to confirm a diagnosis of  
35  
36 empyema from the onset of empyema prodrome. In order to reduce the biased results,  
37  
38 subjects who had an empyema diagnosis within one month after undergoing  
39  
40 splenectomy were excluded from the study. Therefore, it is less possible that  
41  
42 splenectomy could be the cause of the empyema. Fourth, empyema could correlate  
43  
44 very well with open surgery. However, due to the same limitation, the splenectomized  
45  
46 type was not recorded. We did not know how the patients were splenectomized, open  
47  
48 surgery or laparoscopic surgery. Similarly, we did not know that patients underwent  
49  
50 total splenectomy or partial splenectomy. Fifth, lack of vaccination could correlate  
51  
52 very well with empyema. However, due to the same limitation, we did not know how  
53  
54 many of the splenectomized patients were vaccinated against encapsulated bacteria  
55  
56  
57  
58  
59  
60

1  
2  
3 (especially *Streptococcus pneumoniae*). We could not investigate whether  
4 pneumococcal vaccination might decrease the risk of empyema among patients with  
5 splenectomy in Taiwan. Sixth, due to the same limitation, causative pathogens were  
6 not recorded. We could not investigate what kind of bacteria would cause the  
7 empyema among patients with splenectomy. Lack of such information does not permit  
8 the present study to conclude a substantial causality. Further prospective studies are  
9 needed to confirm our findings.  
10  
11

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The strength of this study is that this is the first original study on the association between splenectomy and empyema. Although the underlying mechanism linking splenectomy and empyema cannot be completely determined, our findings are clinically important. In addition, we used a hospitalization dataset with a large sample size and great statistical power. The diagnosis codes of included comorbidities have been documented in previous studies.<sup>18-28</sup> The study design and statistical methods are described in detail. Our results were relatively convincing because the splenectomy group and the non-splenectomy group had similar distributions of studied comorbidities. Therefore, the confounding effects of these comorbidities on risk of empyema should be minimal.

We conclude that patients with splenectomy are associated with 2.89-fold increased risk of empyema, particularly comorbid with other conditions, including alcohol-related diseases, cancers, chronic kidney diseases, chronic liver diseases, chronic obstructive pulmonary diseases, and diabetes mellitus. In the absence of comorbidities, the risk remains high. The incidence rate ratio (IRR) between splenectomy and non-splenectomy from 2.87 reduced to 1.73 after 5 years, but the risk of empyema still existed in the splenectomy group even after 5 years. Future studies are needed to confirm that if the study had an even longer follow up, this average would have gone down further.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Data sharing statement:** no additional data available

### **Acknowledgement**

This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW106-TDU-B-212-113004), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037), National Research Program for Biopharmaceuticals (NRPB) Stroke Clinical Trial Consortium (MOST 105-2325-B-039 -003), Tseng-Lien Lin Foundation in Taichung in Taiwan, Taiwan Brain Disease Foundation in Taipei in Taiwan, and Katsuzo and Kiyoo Aoshima Memorial Funds in Japan. These funding agencies did not influence the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### **Specific author contributions**

Hsien-Feng Lin and Kuan-Fu Liao substantially planned and conducted this study, participated in the data interpretation, and also critically revised the article. Ching-Mei Chang and Cheng-Li Lin conducted the data analysis and critically revised the article.

Shih-Wei Lai substantially planned and conducted this study, contributed to the conception of the article, initiated the draft of the article, and critically revised the article.

### **Conflict of Interest Statement**

The authors disclose no conflicts of interest.

### **Funding statement**

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors

**REFERENCES**

1. Ahmed RA, Marrie TJ, Huang JQ. Thoracic empyema in patients with community-acquired pneumonia. *Am J Med* 2006;119:877-83.
2. Shields T, Locicero J, Ponn R, Rusch V, eds. *General Thoracic Surgery*, 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2005:823.
3. Septimus EJ. Pleural effusion and empyema. In: Mandell GL, Bennet JE, Mandell RD, editors. *Douglas and Bennett's principles and practice of infectious diseases*. Edinburgh: Churchill Livingstone; 2009. pp. 917-24.
4. Spencer RP, Pearson HA. The spleen as a hematological organ. *Semin Nucl Med*. 1975;5:95-102.
5. Trigg ME. Immune function of the spleen. *South Med J*. 1979;72:593-9.
6. Jirillo E, Mastronardi ML, Altamura M, Munno I, Miniello S, Urgesi G, et al. The immunocompromised host: immune alterations in splenectomized patients and clinical implications. *Curr Pharm Des*. 2003;9:1918-23.
7. Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. *Lancet*. 2011;378:86-97.
8. Lai SW, Wang IK, Lin CL, Chen HJ, Liao KF. Splenectomy correlates with increased risk of pulmonary tuberculosis: a case-control study in Taiwan. *Clin Microbiol Infect* 2014;20:764-7.
9. Wu SC, Fu CY, Muo CH, Chang YJ. Splenectomy in trauma patients is associated with an increased risk of postoperative type II diabetes: a nationwide population-based study. *Am J Surg* 2014;208:811-6.
10. Lai SW, Lai HC, Lin CL, Liao KF. Splenectomy Correlates With Increased Risk of Pyogenic Liver Abscess: A Nationwide Cohort Study in Taiwan. *J Epidemiol* 2015;25:561-6.
11. Lai SW, Lin HF, Lin CL, Liao KF. Splenectomy and risk of renal and perinephric abscesses: A population-based cohort study in Taiwan. *Medicine* 2016;95:31(e4438).
12. Lai SW, Lin CL, Liao KF. Splenectomy Correlates With Increased Risk of Acute Pancreatitis: A Case-Control Study in Taiwan. *J Epidemiol* 2016;26:488-92.
13. National Health Insurance Research Database. Taiwan. <http://nhird.nhri.org.tw/en/index.html> [cited in March 1, 2017, English version].
14. Lai SW, Liao KF, Liao CC, Muo CH, Liu CS, Sung FC. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. *Medicine* 2010;89:295-9.
15. Chen HY, Lai SW, Muo CH, Chen PC, Wang IJ. Ethambutol-induced optic neuropathy: a nationwide population-based study from Taiwan. *Br J Ophthalmol*

- 2012;96:1368-71.
16. Yang SP, Muo CH, Wang IK, et al. Risk of type 2 diabetes mellitus in female breast cancer patients treated with morphine: A retrospective population-based time-dependent cohort study. *Diabetes Res Clin Pract* 2015;110:285-90.
  17. Tsai TY, Lin CC, Peng CY, et al. The association between biliary tract inflammation and risk of digestive system cancers: A population-based cohort study. *Medicine* 2016;95:31(e4427).
  18. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. *Am J Gastroenterol* 2012;107:46-52.
  19. Liao KF, Lin CL, Lai SW, Chen WC. Zolpidem Use Associated With Increased Risk of Pyogenic Liver Abscess: A Case-Control Study in Taiwan. *Medicine* 2015;94:32(e1302).
  20. Wong TS, Liao KF, Lin CM, Lin CL, Chen WC, Lai SW. Chronic Pancreatitis Correlates With Increased Risk of Cerebrovascular Disease: A Retrospective Population-Based Cohort Study in Taiwan. *Medicine* 2016;95:15(e3266).
  21. Liao KF, Lai SW, Lin CL, Chien SH. Appendectomy correlates with increased risk of pyogenic liver abscess: A population-based cohort study in Taiwan. *Medicine* 2016;95:26(e4015).
  22. Cheng KC, Lin WY, Liu CS, Lin CC, Lai HC, Lai SW. Association of different types of liver disease with demographic and clinical factors. *BioMedicine-Taiwan* 2016;6:16-22.
  23. Liao KF, Cheng KC, Lin CL, Lai SW. Etodolac and the risk of acute pancreatitis. *BioMedicine-Taiwan* 2017;7:25-9.
  24. Shen ML, Liao KF, Tsai SM, Lin CL, Lai SW. Herpes zoster correlates with pyogenic liver abscesses in Taiwan. *BioMedicine-Taiwan* 2016;6:24-9.
  25. Lai SW. Risks and benefits of zolpidem use in Taiwan: a narrative review. *BioMedicine-Taiwan* 2016;6:9-11.
  26. Lin HF, Lai SW, Lin WY, Liu CS, Lin CC, Chang CM. Prevalence and factors of elevated alanine aminotransferase in central Taiwan - a retrospective study. *BioMedicine-Taiwan* 2016;6:25-30.
  27. Lai SW, Muo CH, Liao KF, Sung FC, Chen PC. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. *Am J Gastroenterol*. 2011;106:1697-704.
  28. Lai HC, Lin CC, Cheng KS, Kao JT, Chou JW, Peng CY, et al. Increased incidence of gastrointestinal cancers among patients with pyogenic liver abscess: a population-based cohort study. *Gastroenterology*. 2014;146:129-37 e1.
  29. Sinwar PD. Overwhelming post splenectomy infection syndrome—review study.

- 1  
2  
3 Int J Surg. 2014;12:1314–6.  
4  
5 30. Eibl M. Immunological consequences of splenectomy. Prog Pediatr Surg.  
6 1985;18:139–45.  
7  
8 31. Van Rooijen N. The humoral immune response in the spleen. Res Immunol.  
9 1991;142:328–30.  
10  
11 32. Altamura M, Caradonna L, Amati L, Pellegrino NM, Urgesi G, Miniello S.  
12 Splenectomy and sepsis: the role of the spleen in the immune-mediated bacterial  
13 clearance. Immunopharmacol Immunotoxicol. 2001;23:153–61.  
14  
15 33. Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among  
16 post-splenectomy patients. J Infect. 2001;43:182–6.  
17  
18 34. Kyaw MH, Holmes EM, Toolis F, Wayne B, Chalmers J, Jones IG, et al.  
19 Evaluation of severe infection and survival after splenectomy. Am J Med.  
20 2006;119:276 e1–7.  
21  
22 35. Dendle C, Sundararajan V, Spelman T, Jolley D, Woolley I. Splenectomy  
23 sequelae: an analysis of infectious outcomes among adults in Victoria. Med J Aust.  
24 2012;196:582–6.  
25  
26 36. Di Cataldo A, Puleo S, Li Destri G, Racalbuto A, Trombatore G, Latteri F, et al.  
27 Splenic trauma and overwhelming postsplenectomy infection. Br J Surg.  
28 1987;74:343–5.  
29  
30 37. Lynch AM, Kapila R. Overwhelming postsplenectomy infection. Infect Dis Clin  
31 North Am. 1996;10:693–707.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Table 1. Baseline characteristics between splenectomy group and non-splenectomy group**

Characteristic	Splenectomy				P value*
	No		Yes		
	N	%	n	%	
Sex					0.88
Female	20431	38.9	5128	38.9	
Male	32033	61.1	8065	61.1	
Age group (years)					0.98
20–39	13415	25.6	3364	25.5	
40–64	24112	46.0	6062	46.0	
65–84	14937	28.5	3767	28.6	
Age (years), mean (standard deviation) <sup>†</sup>	52.5	(17.2)	52.8	(17.2)	0.05
Follow-up period (years), mean (standard deviation) <sup>†</sup>	5.75	(3.32)	4.37	(3.44)	< 0.001
Baseline comorbidities					
Alcohol-related disease	1787	3.41	452	3.43	0.91
Cancers	7677	14.6	1962	14.9	0.49
Chronic kidney disease	1068	2.04	270	2.05	0.94
Chronic liver disease	7791	14.9	1971	14.9	0.80
Chronic obstructive pulmonary disease	2002	3.82	507	3.84	0.89
Diabetes mellitus	7856	15.0	1983	15.0	0.87

Data are presented as the number of subjects in each group, with percentages given in parentheses, or mean with standard deviation given in parentheses.

\*Chi-square test, and <sup>†</sup>t-test comparing subjects with and without splenectomy.

**Table 2. Incidence density of empyema estimated by sex, age, and follow-up period between splenectomy group and non-splenectomy group**

Variable	Non-splenectomy				Splenectomy				IRR <sup>#</sup> (95% CI)
	N	Cases	Person-years	Incidence <sup>†</sup>	N	Cases	Person-years	Incidence <sup>†</sup>	
All	52464	1042	301484	3.46	13193	510	57622	8.85	2.56 (2.44, 2.69)
Sex									
Female	20431	317	119441	2.65	5128	159	23004	6.91	2.60 (2.40, 2.82)
Male	32033	725	182042	3.98	8065	351	34618	10.1	2.55 (2.39, 2.71)
Age group (years)									
20–39	13415	57	84004	0.68	3364	65	19700	3.30	4.86 (4.39, 5.39)
40–64	24112	354	140554	2.52	6062	224	26423	8.48	3.37 (3.13, 3.62)
65–84	14937	631	76925	8.20	3767	221	11499	19.2	2.34 (2.14, 2.56)
Follow-up period (years)									
< 5	52464	720	206010	3.49	13193	416	41545	10.0	2.87 (2.73, 3.01)
≥ 5	28456	322	95474	3.37	5052	94	16077	5.85	1.73 (1.60, 1.88)

<sup>†</sup> Incidence rate: per 1,000 person-years.

<sup>#</sup>IRR (incidence rate ratio): splenectomy vs. non-splenectomy (95% CI)

**Table 3. Adjusted hazard ratio and 95% confidence interval of empyema associated with splenectomy and other comorbidities**

Variable	Crude	Adjusted <sup>†</sup>
	HR (95%CI)	HR (95%CI)
Sex (male vs. female)	1.48 (1.33, 1.65)	1.51 (1.35, 1.68)
Age (per one year)	1.05 (1.04, 1.05)	1.05 (1.05, 1.06)
Baseline comorbidities (yes vs. no)		
<b>Splenectomy</b>	<b>2.52 (2.26, 2.80)</b>	<b>2.89 (2.60, 3.22)</b>
Alcohol-related disease	1.61 (1.28, 2.03)	2.25 (1.76, 2.86)
Cancers	2.60 (2.31, 2.92)	1.92 (1.71, 2.17)
Chronic kidney disease	3.04 (2.40, 3.85)	2.13 (1.67, 2.70)
Chronic liver disease	2.07 (1.84, 2.34)	1.90 (1.68, 2.14)
Chronic obstructive pulmonary disease	3.95 (3.37, 4.64)	1.75 (1.48, 2.07)
Diabetes mellitus	2.80 (2.51, 3.13)	1.85 (1.65, 2.07)

<sup>†</sup>Variables found to be statistically significant in the univariable model were further examined in the multivariable model. Adjusted for age, sex, alcohol-related disease, cancers, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease, and diabetes mellitus

**Table 4. Cox proportional hazard regression analysis for risk of empyema stratified by splenectomy and comorbidities**

Variable		Event	Incidence <sup>†</sup>	Adjusted HR <sup>#</sup> (95% CI)
Splenectomy	Any comorbidity*			
No	No	299	1.49	1(Reference)
No	Yes	743	7.34	3.64(3.18, 4.17)
Yes	No	230	5.75	4.52(3.80, 5.37)
Yes	Yes	280	15.9	8.23(6.98, 9.70)

<sup>†</sup> Incidence rate: per 1,000 person-years

<sup>#</sup> Adjusted for sex and age


\*Comorbidities including alcohol-related disease, cancers, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease, and diabetes mellitus

95% CI: 95% confidence interval

1  
2  
3  
4 Fig 1: Kaplan-Meier model revealed that the splenectomy group had a higher  
5  
6 cumulative incidence of pleural empyema than the non-splenectomy group  
7  
8 (6.99% vs. 3.37% at the end of follow-up;  $P < 0.001$ )  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



190x107mm (300 x 300 DPI)

review only

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	
<b>Introduction</b>				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3	
Objectives	3	State specific objectives, including any prespecified hypotheses	3,4	
<b>Methods</b>				
Study design	4	Present key elements of study design early in the paper	4	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	4	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5	
Bias	9	Describe any efforts to address potential sources of bias	4,5	
Study size	10	Explain how the study size was arrived at	4	

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5
		(b) Describe any methods used to examine subgroups and interactions	5
		(c) Explain how missing data were addressed	5
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	5
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	6
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	7,8
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8
		(b) Report category boundaries when continuous variables were categorized	8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	8

Continued on next page



Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10-12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Population-based cohort study examining the association between splenectomy and empyema in adults in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015101.R3
Article Type:	Research
Date Submitted by the Author:	23-May-2017
Complete List of Authors:	Lin, Hsien-Feng; China Medical University Hospital, ; Liao, Kuan-Fu Chang, Ching-Mei Lin, Cheng-Li Lai, Shih-Wei; China Medical University Hospital, Department of Family Medicine
<b>Primary Subject Heading</b>:	General practice / Family practice
Secondary Subject Heading:	Gastroenterology and hepatology
Keywords:	empyema, splenectomy, Taiwan National Health Insurance Program

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Type of manuscript: Original article

**Manuscript title: Population-based cohort study examining the association between splenectomy and empyema in adults in Taiwan**

□ Running head: splenectomy and empyema

• Authors' full names:

Hsien-Feng Lin MD and MS<sup>1,2</sup>; Kuan-Fu Liao MD and PhD<sup>3,4,5</sup>; Ching-Mei Chang RN and MSN<sup>6</sup>; Cheng-Li Lin MS<sup>7,8</sup>; Shih-Wei Lai MD<sup>2,7</sup>

• (The first three authors contributed equally to this study)

• <sup>1</sup>School of Chinese Medicine, <sup>5</sup>Graduate Institute of Integrated Medicine, and <sup>7</sup>College of Medicine, China Medical University, Taichung, Taiwan.

• <sup>3</sup>Department of Internal Medicine, Taichung Tzu Chi General Hospital, Taichung, Taiwan

• <sup>4</sup>College of Medicine, Tzu Chi University, Hualien, Taiwan

• <sup>2</sup>Department of Family Medicine and <sup>8</sup>Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan.

• <sup>6</sup>Assistant Professor and Deputy Director, Department of Nursing, Tungs' Taichung Metro Harbor Hospital, Taichung, Taiwan

• Corresponding author: Shih-Wei Lai, Department of Family Medicine, China Medical University Hospital, No 2, Yuh-Der Road, Taichung City, 404, Taiwan

Phone: 886-4-2205-2121; Fax: 886-4-2203-3986

E-mail: wei@mail.cmuh.org.tw

## ABSTRACT

**Objectives.** Little is known about the risk of empyema in patients with splenectomy. We investigate the relationship between splenectomy and empyema in Taiwan.

**Methods.** We conducted a population-based cohort analysis using the hospitalization dataset of the Taiwan National Health Insurance Program. There were 13193 subjects aged 20 to 84 years who were newly diagnosed with splenectomy in 2000 to 2010 as the splenectomy group and 52464 randomly selected subjects without splenectomy as the non-splenectomy group. Both groups were matched by sex, age, comorbidities, and hospitalization year of undergoing splenectomy. The incidence of empyema at the end of 2011 was calculated. The multivariable Cox proportional hazards regression model was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for empyema associated with splenectomy and other comorbidities. **Results.** The overall incidence rate of empyema was 2.56-fold higher in the splenectomy group than that in the non-splenectomy group (8.85 vs. 3.46 per 1,000 person-years, 95% CI 2.44, 2.69). The Kaplan-Meier model revealed that the splenectomy group had a higher cumulative incidence of empyema than the non-splenectomy group (6.99% vs. 3.37% at the end of follow-up). After adjusted for confounders, the adjusted HR of empyema was 2.89 in subjects with splenectomy (95%CI 2.60, 3.22), compared with subjects without splenectomy. In further analysis, in the absence of comorbidities studied, the HR was 4.52 for those with splenectomy alone (95% CI=3.80, 5.37). **Conclusions.** The incidence rate ratio between splenectomy and non-splenectomy from 2.87 reduced to 1.73 after 5 years, but the risk of empyema still existed in the splenectomy group. Patients with splenectomy are associated with 2.89-fold increased risk of empyema. In the absence of comorbidities, the risk remains high. Future studies are needed to confirm that if the study had an even longer follow up, this average would have gone down further.

**Keywords:** empyema; splenectomy; Taiwan National Health Insurance Program

### Strengths and limitations of this study.

1. This is the first original study on the association between splenectomy and empyema.
2. We used a hospitalization dataset with a large sample size and great statistical power.
3. Some traditional behavior risk factors including alcohol consumption and cigarette smoking were not recorded due to the inherent limitation of this insurance database.
4. The underlying causes for splenectomy in this present study were not recorded

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

due to the inherent limitation of this insurance database.

- 5. Such a study design does not permit to conclude a substantial causality.

For peer review only

## INTRODUCTION

Empyema is a suppurative infection of the pleural space. The creation of empyema can be divided into two distinct mechanisms. Empyema occurs most commonly after pneumonia, with direct spread of organisms into the pleural space. This occurs in approximately 1% to 5% of pneumonias.<sup>1,2</sup> The other mechanism occurs after surgery, most commonly of the thorax, esophagus, lung or heart. Empyema is an ancient disease that continues to be an important clinical problem nowadays. Despite the centuries of learned experience, the appearance of antibiotics and the use of different pneumococcal vaccines, empyema remains the most common complication of pneumonia and an important cause of morbidity worldwide.<sup>3</sup> The incidence of pleural infections diminished significantly during the first half of the 20th century because of the development of antibiotics. However, this trend changed at the end of the 20th century and, since the decade of the 1990s the incidence of empyema has tended to be increasing worldwide.

The human spleen mainly serves an immune function against invading microorganisms.<sup>4,5</sup> The immunologic and hematologic functions of the spleen in humans are well known. Specifically, the spleen protects against infections mediated by innate and adaptive immunity.<sup>6,7</sup> Patients with splenectomy are more likely than those without splenectomy to suffer severe life-threatening infections. Splenectomy is associated with increased risk of some diseases, including pulmonary tuberculosis, type 2 diabetes mellitus, pyogenic liver abscess, renal and perinephric abscesses, and acute pancreatitis,<sup>8-12</sup> but empyema has not yet been studied.

Despite the incidence of empyema has tended to be increasing worldwide, no study has evaluated the association between splenectomy and empyema. We rationally hypothesize an association between splenectomy and empyema due to the immunocompromised condition caused by splenectomy, which can further increase

1  
2  
3 the risk of microorganism invasion of the pleural space. However, published literature  
4 from epidemiological studies on this issue is scarce. Given that splenectomy is  
5 associated with overwhelming postsplenectomy infections and empyema carries a  
6 potential fatality, exploring the risk of empyema in patients with splenectomy may  
7 have significant clinical and public health implications. Therefore, to explore whether  
8 there is an association between splenectomy and empyema, we conducted a  
9 nationwide cohort study using the hospitalization dataset of the Taiwan National  
10 Health Insurance Program.  
11  
12  
13  
14  
15  
16  
17  
18  
19

## 20 **METHODS**

### 21 **Study design and data source**

22  
23  
24  
25 Taiwan is an independent country with more than 23 million people. We conducted  
26 a population-based cohort study using insurance claim data from the Taiwan National  
27 Health Insurance Program which covers 99% of the whole Taiwan population since  
28 1995.<sup>13</sup> The details of the insurance program have been well written in previous  
29 studies.<sup>14-17</sup> The study was approved by the Research Ethics Committee of China  
30 Medical University and Hospital in Taiwan (CMUH-104-REC2-115).  
31  
32  
33  
34  
35  
36  
37

### 38 **Sampled Participants**

39  
40 Using the hospitalization dataset of the Taiwan National Health Insurance Program,  
41 all hospitalized subjects aged 20 to 84 who underwent splenectomy (International  
42 Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9 procedure  
43 code 41.5) between January 1, 2000 and December 31, 2010, were identified as the  
44 splenectomy group. The date for undergoing splenectomy was defined as the index  
45 date. For each subject with splenectomy, 4 subjects without splenectomy were  
46 randomly selected from the same database as the non-splenectomy group. Both  
47 groups were matched by sex, age (every 5-year span), comorbidities, and the  
48 hospitalization year of undergoing splenectomy. To reduce the biased results, subjects  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 who had an empyema diagnosis (ICD-9 codes 510, 511.1, 511.8, and 511.9) within  
4 one month after undergoing splenectomy were excluded from the study.  
5  
6

### 7 8 **Outcome and Comorbidities**

9  
10 The main outcome was a new diagnosis of empyema based on hospital discharge  
11 registries during the follow-up period. Each subject was monitored from the index  
12 date until being diagnosed with empyema, or being censored because of loss to  
13 follow-up, death, or withdrawal from insurance, or to the end of December 31, 2011.  
14  
15 Comorbidities investigated in the study were included as follows: alcohol-related  
16 disease, cancers, chronic kidney disease, chronic liver disease (including cirrhosis,  
17 alcoholic liver damage, hepatitis B, hepatitis C, and other chronic hepatitis), chronic  
18 obstructive pulmonary disease, and diabetes mellitus. All comorbidities were  
19 diagnosed with ICD-9 codes, which have been well assessed in previous studies.<sup>18-28</sup>  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 30 **Statistical analysis**

31  
32 The differences between sex, age, and comorbidities between the splenectomy group  
33 and the non-splenectomy group were compared by using the Chi-square test for  
34 categorical variables, and *t*-test for continuous variables. Follow-up time  
35 (person-years) was used to estimate the incidence rate and incidence rate ratio (IRR)  
36 with 95% confidence interval (CI) of splenectomy group to non-splenectomy group  
37 using Poisson regression, by sex, age, and follow-up period. The multivariable Cox  
38 proportional hazards regression model was used to estimate the hazard ratio (HR)  
39 with 95% confidence interval (CI) of empyema associated with splenectomy and  
40 other comorbidities after simultaneously adjusted for variables found to be significant  
41 in the univariable Cox proportion hazard regression model. The proportional hazard  
42 model assumption was examined by using a test of scaled Schoenfeld residuals. In the  
43 model evaluating empyema risk throughout the overall follow-up period, results of the  
44 test revealed a significant relationship between Schoenfeld residuals for splenectomy  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 and follow-up time, suggesting the proportionality assumption was violated ( $P$  value  
4 < 0.001). In the subsequent analysis, we stratified the follow-up period to deal with  
5  
6 the violation of proportional hazard assumption. All statistical analyses were  
7  
8 performed using SAS 9.2 (SAS Institute, Cary, North Carolina, USA). Two-tailed  $P$  <  
9  
10 0.05 was considered statistically significant.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## RESULTS

### Baseline information of the study population

Table 1 discloses the baseline information of the study population. There were 13193 subjects with splenectomy and 52464 subjects without splenectomy during the study period, with similar distributions in sex and age. The mean ages (mean  $\pm$  standard deviation) were  $52.8 \pm 17.2$  years in the splenectomy group and  $52.5 \pm 17.2$  years in the non-splenectomy group (*t* test, *P* = 0.05). The mean follow-up periods (mean  $\pm$  standard deviation) were  $4.37 \pm 3.44$  years in the splenectomy group and  $5.75 \pm 3.32$  years in the non-splenectomy group (*t* test, *P* < 0.001). There was no significant difference in the prevalence of comorbidities studied between the splenectomy group and the non-splenectomy group (Chi-square test, *P* > 0.05 for all).

### Incidence of empyema stratified by sex, age, and follow-up period

Table 2 discloses the incidence rates of empyema. At the end of the cohort study, the overall incidence rate of empyema was 2.56-fold higher in the splenectomy group than that in the non-splenectomy group (8.85 vs. 3.46 per 1,000 person-years, 95% CI 2.44, 2.69). The incidence rates of empyema, as stratified by sex, age, and follow-up period, were all higher in the splenectomy group than those in the non-splenectomy group. The incidence rates of empyema increased with age in both groups, with the highest in the splenectomy group aged 65 to 84 years (19.2 per 1,000 person-years). Stratified analysis by follow-up period disclosed that the incidence rates of empyema decreased with the follow-up time in both groups. The risk of empyema in the splenectomy group was significantly higher in the first 5 years of follow-up (incidence rate ratio 2.87, 95% CI 2.73, 3.01). However, the risk of empyema still existed in the splenectomy group even after 5 years (incidence rate ratio 1.73, 95% CI 1.60, 1.88).

In Figure 1, the Kaplan-Meier model revealed that the splenectomy group had a

1  
2  
3 higher cumulative incidence of pleural empyema than the non-splenectomy group  
4  
5 (6.99% vs. 3.37% at the end of follow-up;  $P < 0.001$ ).  
6  
7

### 8 9 10 **Hazard ratio of empyema associated with splenectomy and other comorbidities**

11  
12 Table 3 discloses the HR of empyema associated with splenectomy and other  
13 comorbidities. Variable found to be statistically significant in the univariable model  
14 were further examined in the multivariable model. After adjusted for age, sex,  
15 alcohol-related disease, cancers, chronic kidney disease, chronic liver disease, chronic  
16 obstructive pulmonary disease, and diabetes mellitus, the multivariable Cox  
17 proportional hazards regression model disclosed that the adjusted HR of empyema  
18 was 2.89 in subjects with splenectomy (95% CI 2.60, 3.22), compared with subjects  
19 without splenectomy.  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 **Interaction effect on risk of empyema between splenectomy and other** 30 **comorbidities**

31  
32 Table 4 discloses interaction effect on risk of empyema between splenectomy and  
33 other comorbidities including alcohol-related diseases, cancers, chronic kidney  
34 diseases, chronic liver diseases, chronic obstructive pulmonary diseases, and diabetes  
35 mellitus. As a reference of subjects without splenectomy and without any comorbidity,  
36 the adjusted HR of empyema was 4.52 for subjects with splenectomy alone and  
37 without any comorbidity (95% CI 3.80, 5.37). The HR markedly increased to 8.23 for  
38 those with splenectomy and comorbid with any comorbidity (95% CI 6.98, 9.70). It  
39 means that there is an interaction effect on risk of empyema between splenectomy and  
40 other comorbidities.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

A review by Sinwar found that the duration between splenectomy and onset of overwhelming post-splenectomy infection could range from less than 1 week to more than 20 years.<sup>29</sup> To diminish biased results, we excluded patients who underwent splenectomy within 1 month of empyema diagnosis to ensure that splenectomy truly preceded the onset of empyema.

Extensive evidence has revealed that the human spleen mainly serves a protective role against invading microorganisms on the basis of bactericidal capacity of lymphoid cells and macrophages and the humoral immune response.<sup>6,30-32</sup> Upon removal of the spleen, normal immune functions, such as phagocytic activities and the humoral immune response, may be significantly changed. Therefore, impaired immune functions after splenectomy may increase the risk of life-threatening infection and empyema. In our study, the risk of empyema in the splenectomy group was higher in the first 5 years of follow-up than after 5 years (incidence rate ratio 2.87 vs 1.73). However, the risk of empyema still existed in the splenectomy group even after 5 years. These findings are compatible with previous studies showing that the majority of severe infections occur within the first 3 years after splenectomy, and, although the risk declines over time, the risk might last for more than 5 years after splenectomy.<sup>33-35</sup> The mechanism remains unknown. We speculate that with time, the immune system could develop ways to compensate or overcome these immune deficits. So the risk of empyema in the splenectomy group was higher in the first 5 years of follow-up. Future studies are needed to confirm this hypothesis.

In this population-based cohort study, we noticed that splenectomy was associated with increased hazard ratio of empyema (adjusted HR 2.89). To the best of our knowledge, this is the first population-based cohort study to examine this issue. Some studies have found that splenectomy is associated with increased risk of some diseases.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Lai et al. found that the adjusted odds ratio of acute pancreatitis was 2.90 for subjects with splenectomy (95% CI, 1.39–6.05) compared with subjects without splenectomy,<sup>12</sup> the adjusted hazard ratio of renal and perinephric abscesses was 2.24 for the splenectomy group (95% CI, 1.30–3.88) when compared with the non-splenectomy group,<sup>11</sup> the adjusted hazard ratio of pyogenic liver abscess was 3.89 in subjects with splenectomy (95% confidence interval, 3.20–4.72) when compared with subjects without splenectomy,<sup>10</sup> and the odds of pulmonary tuberculosis were 1.91 in patients with splenectomy (95% CI 1.06–3.44) compared with the participants without splenectomy.<sup>8</sup>

In this study, after controlling for potential confounding factors, we also observed that patients with splenectomy were at increased risk of empyema (adjusted HR 2.89). The phenomenon that would normally be regarded as counter-intuitive and the reason were unclear. It may be due to some comorbidities which could be potentially related to empyema should be included in the study, but we lose them. Future studies are needed to explain this phenomenon. The HR seems to be higher than that observed for comorbidities. The HR was not confounded by comorbidities studied because there was no significant difference in the prevalence of comorbidities between the splenectomy group and the non-splenectomy group. It means the increased hazard of empyema in patients with splenectomy cannot be totally attributable to the effect of comorbidities. Though these comorbidities were found to be associated with empyema, to minimize their confounding effects, we made a further analysis, in absence of any comorbidity, patients with splenectomy still had a higher hazard of empyema (HR 4.52). These results indicate that not requiring the presence of comorbidity, splenectomy may have a unique role on risk of empyema. These findings are compatible with the literature that patients with splenectomy are not only more prone to suffer severe life-threatening infection due to the immunocompromised

1  
2  
3 condition caused by splenectomy<sup>36,37</sup> but also at an increased hazard of developing  
4  
5 empyema.  
6

7  
8 Some limitations in the present study deserve discussion. First, some traditional  
9  
10 behavior risk factors including alcohol consumption and cigarette smoking were not  
11  
12 recorded due to the inherent limitation of this insurance database. We used  
13  
14 alcohol-related diseases instead of alcohol consumption and chronic obstructive  
15  
16 pulmonary disease instead of cigarette smoking. Second, the underlying causes for  
17  
18 splenectomy in this present study were not recorded due to the inherent limitation of  
19  
20 this insurance database. Splenectomy is commonly underwent in certain disorders and  
21  
22 diseases, such as hematological disorders, gastric cancer, or trauma, so these  
23  
24 background conditions might confound the results. Whether the reasons for  
25  
26 splenectomy are associated with empyema cannot be clarified in this study. Third,  
27  
28 Due to the inherent limitation of this insurance database, the underlying causes for  
29  
30 splenectomy were not recorded. The cause of splenectomy could be the cause of the  
31  
32 empyema, for example, splenic abscess. From a view of the good quality of the  
33  
34 Taiwan medical system, it does not need to spend one month to confirm a diagnosis of  
35  
36 empyema from the onset of empyema prodrome. In order to reduce the biased results,  
37  
38 subjects who had an empyema diagnosis within one month after undergoing  
39  
40 splenectomy were excluded from the study. Therefore, it is less possible that  
41  
42 splenectomy could be the cause of the empyema. Fourth, empyema could correlate  
43  
44 very well with open surgery. However, due to the same limitation, the splenectomized  
45  
46 type was not recorded. We did not know how the patients were splenectomized, open  
47  
48 surgery or laparoscopic surgery. Similarly, we did not know that patients underwent  
49  
50 total splenectomy or partial splenectomy. Fifth, lack of vaccination could correlate  
51  
52 very well with empyema. However, due to the same limitation, we did not know how  
53  
54 many of the splenectomized patients were vaccinated against encapsulated bacteria  
55  
56  
57  
58  
59  
60

1  
2  
3 (especially *Streptococcus pneumoniae*). We could not investigate whether  
4  
5 pneumococcal vaccination might decrease the risk of empyema among patients with  
6  
7 splenectomy in Taiwan. Sixth, due to the same limitation, causative pathogens were  
8  
9 not recorded. We could not investigate what kind of bacteria would cause the  
10  
11 empyema among patients with splenectomy. Lack of such information does not permit  
12  
13 the present study to conclude a substantial causality. Further prospective studies are  
14  
15 needed to confirm our findings.  
16  
17

18  
19 The strength of this study is that this is the first original study on the association  
20  
21 between splenectomy and empyema. Although the underlying mechanism linking  
22  
23 splenectomy and empyema cannot be completely determined, our findings are  
24  
25 clinically important. In addition, we used a hospitalization dataset with a large sample  
26  
27 size and great statistical power. The diagnosis codes of included comorbidities have  
28  
29 been documented in previous studies.<sup>18-28</sup> The study design and statistical methods  
30  
31 are described in detail. Our results were relatively convincing because the  
32  
33 splenectomy group and the non-splenectomy group had similar distributions of  
34  
35 studied comorbidities. Therefore, the confounding effects of these comorbidities on  
36  
37 risk of empyema should be minimal.  
38  
39

40  
41 We conclude that the incidence rate ratio between splenectomy and  
42  
43 non-splenectomy from 2.87 reduced to 1.73 after 5 years, but the risk of empyema  
44  
45 still existed in the splenectomy group even after 5 years. Patients with splenectomy  
46  
47 are associated with 2.89-fold increased risk of empyema, particularly comorbid with  
48  
49 other conditions, including alcohol-related diseases, cancers, chronic kidney diseases,  
50  
51 chronic liver diseases, chronic obstructive pulmonary diseases, and diabetes mellitus.  
52  
53 In the absence of comorbidities, the risk remains high. Future studies are needed to  
54  
55 confirm that if the study had an even longer follow up, this average would have gone  
56  
57 down further.  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Data sharing statement:** no additional data available

### **Acknowledgement**

This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW106-TDU-B-212-113004), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037), National Research Program for Biopharmaceuticals (NRPB) Stroke Clinical Trial Consortium (MOST 105-2325-B-039 -003), Tseng-Lien Lin Foundation in Taichung in Taiwan, Taiwan Brain Disease Foundation in Taipei in Taiwan, and Katsuzo and Kiyoo Aoshima Memorial Funds in Japan. These funding agencies did not influence the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### **Specific author contributions**

Hsien-Feng Lin and Kuan-Fu Liao substantially planned and conducted this study, participated in the data interpretation, and also critically revised the article. Ching-Mei Chang and Cheng-Li Lin conducted the data analysis and critically revised the article.

Shih-Wei Lai substantially planned and conducted this study, contributed to the conception of the article, initiated the draft of the article, and critically revised the article.

### **Conflict of Interest Statement**

The authors disclose no conflicts of interest.

### **Funding statement**

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors



**REFERENCES**

1. Ahmed RA, Marrie TJ, Huang JQ. Thoracic empyema in patients with community-acquired pneumonia. *Am J Med* 2006;119:877-83.
2. Shields T, Locicero J, Ponn R, Rusch V, eds. *General Thoracic Surgery*, 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2005:823.
3. Septimus EJ. Pleural effusion and empyema. In: Mandell GL, Bennet JE, Mandell RD, editors. *Douglas and Bennett's principles and practice of infectious diseases*. Edinburgh: Churchill Livingstone; 2009. pp. 917-24.
4. Spencer RP, Pearson HA. The spleen as a hematological organ. *Semin Nucl Med*. 1975;5:95-102.
5. Trigg ME. Immune function of the spleen. *South Med J*. 1979;72:593-9.
6. Jirillo E, Mastronardi ML, Altamura M, Munno I, Miniello S, Urgesi G, et al. The immunocompromised host: immune alterations in splenectomized patients and clinical implications. *Curr Pharm Des*. 2003;9:1918-23.
7. Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. *Lancet*. 2011;378:86-97.
8. Lai SW, Wang IK, Lin CL, Chen HJ, Liao KF. Splenectomy correlates with increased risk of pulmonary tuberculosis: a case-control study in Taiwan. *Clin Microbiol Infect* 2014;20:764-7.
9. Wu SC, Fu CY, Muo CH, Chang YJ. Splenectomy in trauma patients is associated with an increased risk of postoperative type II diabetes: a nationwide population-based study. *Am J Surg* 2014;208:811-6.
10. Lai SW, Lai HC, Lin CL, Liao KF. Splenectomy Correlates With Increased Risk of Pyogenic Liver Abscess: A Nationwide Cohort Study in Taiwan. *J Epidemiol* 2015;25:561-6.
11. Lai SW, Lin HF, Lin CL, Liao KF. Splenectomy and risk of renal and perinephric abscesses: A population-based cohort study in Taiwan. *Medicine* 2016;95:31(e4438).
12. Lai SW, Lin CL, Liao KF. Splenectomy Correlates With Increased Risk of Acute Pancreatitis: A Case-Control Study in Taiwan. *J Epidemiol* 2016;26:488-92.
13. National Health Insurance Research Database. Taiwan. <http://nhird.nhri.org.tw/en/index.html> [cited in March 1, 2017, English version].
14. Lai SW, Liao KF, Liao CC, Muo CH, Liu CS, Sung FC. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. *Medicine* 2010;89:295-9.
15. Chen HY, Lai SW, Muo CH, Chen PC, Wang IJ. Ethambutol-induced optic neuropathy: a nationwide population-based study from Taiwan. *Br J Ophthalmol*

- 2012;96:1368-71.
16. Yang SP, Muo CH, Wang IK, et al. Risk of type 2 diabetes mellitus in female breast cancer patients treated with morphine: A retrospective population-based time-dependent cohort study. *Diabetes Res Clin Pract* 2015;110:285-90.
  17. Tsai TY, Lin CC, Peng CY, et al. The association between biliary tract inflammation and risk of digestive system cancers: A population-based cohort study. *Medicine* 2016;95:31(e4427).
  18. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. *Am J Gastroenterol* 2012;107:46-52.
  19. Liao KF, Lin CL, Lai SW, Chen WC. Zolpidem Use Associated With Increased Risk of Pyogenic Liver Abscess: A Case-Control Study in Taiwan. *Medicine* 2015;94:32(e1302).
  20. Wong TS, Liao KF, Lin CM, Lin CL, Chen WC, Lai SW. Chronic Pancreatitis Correlates With Increased Risk of Cerebrovascular Disease: A Retrospective Population-Based Cohort Study in Taiwan. *Medicine* 2016;95:15(e3266).
  21. Liao KF, Lai SW, Lin CL, Chien SH. Appendectomy correlates with increased risk of pyogenic liver abscess: A population-based cohort study in Taiwan. *Medicine* 2016;95:26(e4015).
  22. Cheng KC, Lin WY, Liu CS, Lin CC, Lai HC, Lai SW. Association of different types of liver disease with demographic and clinical factors. *BioMedicine-Taiwan* 2016;6:16-22.
  23. Liao KF, Cheng KC, Lin CL, Lai SW. Etodolac and the risk of acute pancreatitis. *BioMedicine-Taiwan* 2017;7:25-9.
  24. Shen ML, Liao KF, Tsai SM, Lin CL, Lai SW. Herpes zoster correlates with pyogenic liver abscesses in Taiwan. *BioMedicine-Taiwan* 2016;6:24-9.
  25. Lai SW. Risks and benefits of zolpidem use in Taiwan: a narrative review. *BioMedicine-Taiwan* 2016;6:9-11.
  26. Lin HF, Lai SW, Lin WY, Liu CS, Lin CC, Chang CM. Prevalence and factors of elevated alanine aminotransferase in central Taiwan - a retrospective study. *BioMedicine-Taiwan* 2016;6:25-30.
  27. Lai SW, Muo CH, Liao KF, Sung FC, Chen PC. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. *Am J Gastroenterol*. 2011;106:1697-704.
  28. Liao KF, Huang PT, Lin CC, Lin CL, Lai SW. Fluvastatin use and risk of acute pancreatitis: a population-based case-control study in Taiwan. *BioMedicine-Taiwan* 2017;7:1-5.
  29. Sinwar PD. Overwhelming post splenectomy infection syndrome—review study.

- 1  
2  
3 Int J Surg. 2014;12:1314–6.  
4  
5 30. Eibl M. Immunological consequences of splenectomy. Prog Pediatr Surg.  
6 1985;18:139–45.  
7  
8 31. Van Rooijen N. The humoral immune response in the spleen. Res Immunol.  
9 1991;142:328–30.  
10  
11 32. Altamura M, Caradonna L, Amati L, Pellegrino NM, Urgesi G, Miniello S.  
12 Splenectomy and sepsis: the role of the spleen in the immune-mediated bacterial  
13 clearance. Immunopharmacol Immunotoxicol. 2001;23:153–61.  
14  
15 33. Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among  
16 post-splenectomy patients. J Infect. 2001;43:182–6.  
17  
18 34. Kyaw MH, Holmes EM, Toolis F, Wayne B, Chalmers J, Jones IG, et al.  
19 Evaluation of severe infection and survival after splenectomy. Am J Med.  
20 2006;119:276 e1–7.  
21  
22 35. Dendle C, Sundararajan V, Spelman T, Jolley D, Woolley I. Splenectomy  
23 sequelae: an analysis of infectious outcomes among adults in Victoria. Med J Aust.  
24 2012;196:582–6.  
25  
26 36. Di Cataldo A, Puleo S, Li Destri G, Racalbuto A, Trombatore G, Latteri F, et al.  
27 Splenic trauma and overwhelming postsplenectomy infection. Br J Surg.  
28 1987;74:343–5.  
29  
30 37. Lynch AM, Kapila R. Overwhelming postsplenectomy infection. Infect Dis Clin  
31 North Am. 1996;10:693–707.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1. Baseline characteristics between splenectomy group and non-splenectomy group**

Characteristic	Splenectomy				P value*
	No		Yes		
	N=52464		N=13193		
	N	%	n	%	
Sex					0.88
Female	20431	38.9	5128	38.9	
Male	32033	61.1	8065	61.1	
Age group (years)					0.98
20–39	13415	25.6	3364	25.5	
40–64	24112	46.0	6062	46.0	
65–84	14937	28.5	3767	28.6	
Age (years), mean (standard deviation) <sup>†</sup>	52.5	(17.2)	52.8	(17.2)	0.05
Follow-up period (years), mean (standard deviation) <sup>†</sup>	5.75	(3.32)	4.37	(3.44)	< 0.001
Baseline comorbidities					
Alcohol-related disease	1787	3.41	452	3.43	0.91
Cancers	7677	14.6	1962	14.9	0.49
Chronic kidney disease	1068	2.04	270	2.05	0.94
Chronic liver disease	7791	14.9	1971	14.9	0.80
Chronic obstructive pulmonary disease	2002	3.82	507	3.84	0.89
Diabetes mellitus	7856	15.0	1983	15.0	0.87

Data are presented as the number of subjects in each group, with percentages given in parentheses, or mean with standard deviation given in parentheses.

\*Chi-square test, and <sup>†</sup>t-test comparing subjects with and without splenectomy.

**Table 2. Incidence density of empyema estimated by sex, age, and follow-up period between splenectomy group and non-splenectomy group**

Variable	Non-splenectomy				Splenectomy				IRR <sup>#</sup> (95% CI)
	N	Cases	Person-years	Incidence <sup>†</sup>	N	Cases	Person-years	Incidence <sup>†</sup>	
All	52464	1042	301484	3.46	13193	510	57622	8.85	2.56 (2.44, 2.69)
Sex									
Female	20431	317	119441	2.65	5128	159	23004	6.91	2.60 (2.40, 2.82)
Male	32033	725	182042	3.98	8065	351	34618	10.1	2.55 (2.39, 2.71)
Age group (years)									
20–39	13415	57	84004	0.68	3364	65	19700	3.30	4.86 (4.39, 5.39)
40–64	24112	354	140554	2.52	6062	224	26423	8.48	3.37 (3.13, 3.62)
65–84	14937	631	76925	8.20	3767	221	11499	19.2	2.34 (2.14, 2.56)
Follow-up period (years)									
< 5	52464	720	206010	3.49	13193	416	41545	10.0	2.87 (2.73, 3.01)
≥ 5	28456	322	95474	3.37	5052	94	16077	5.85	1.73 (1.60, 1.88)

<sup>†</sup> Incidence rate: per 1,000 person-years.

<sup>#</sup>IRR (incidence rate ratio): splenectomy vs. non-splenectomy (95% CI)

**Table 3. Adjusted hazard ratio and 95% confidence interval of empyema associated with splenectomy and other comorbidities**

Variable	Crude	Adjusted <sup>†</sup>
	HR (95%CI)	HR (95%CI)
Sex (male vs. female)	1.48 (1.33, 1.65)	1.51 (1.35, 1.68)
Age (per one year)	1.05 (1.04, 1.05)	1.05 (1.05, 1.06)
Baseline comorbidities (yes vs. no)		
<b>Splenectomy</b>	<b>2.52 (2.26, 2.80)</b>	<b>2.89 (2.60, 3.22)</b>
Alcohol-related disease	1.61 (1.28, 2.03)	2.25 (1.76, 2.86)
Cancers	2.60 (2.31, 2.92)	1.92 (1.71, 2.17)
Chronic kidney disease	3.04 (2.40, 3.85)	2.13 (1.67, 2.70)
Chronic liver disease	2.07 (1.84, 2.34)	1.90 (1.68, 2.14)
Chronic obstructive pulmonary disease	3.95 (3.37, 4.64)	1.75 (1.48, 2.07)
Diabetes mellitus	2.80 (2.51, 3.13)	1.85 (1.65, 2.07)

<sup>†</sup>Variables found to be statistically significant in the univariable model were further examined in the multivariable model. Adjusted for age, sex, alcohol-related disease, cancers, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease, and diabetes mellitus

**Table 4. Cox proportional hazard regression analysis for risk of empyema stratified by splenectomy and comorbidities**

Variable		Event	Incidence <sup>†</sup>	Adjusted HR <sup>#</sup> (95% CI)
Splenectomy	Any comorbidity*			
No	No	299	1.49	1(Reference)
No	Yes	743	7.34	3.64(3.18, 4.17)
Yes	No	230	5.75	4.52(3.80, 5.37)
Yes	Yes	280	15.9	8.23(6.98, 9.70)

<sup>†</sup> Incidence rate: per 1,000 person-years

<sup>#</sup> Adjusted for sex and age

\*Comorbidities including alcohol-related disease, cancers, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease, and diabetes mellitus


95% CI: 95% confidence interval

1  
2  
3  
4  
5  
6 **Fig 1: Kaplan-Meier model revealed that the splenectomy group had a higher**  
7  
8 **cumulative incidence of pleural empyema than the non-splenectomy**  
9  
10 **group (6.99% vs. 3.37% at the end of follow-up;  $P < 0.001$ )**  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



190x107mm (300 x 300 DPI)

review only

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	
<b>Introduction</b>				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3	
Objectives	3	State specific objectives, including any prespecified hypotheses	3,4	
<b>Methods</b>				
Study design	4	Present key elements of study design early in the paper	4	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	4	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5	
Bias	9	Describe any efforts to address potential sources of bias	4,5	
Study size	10	Explain how the study size was arrived at	4	

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5
		(b) Describe any methods used to examine subgroups and interactions	5
		(c) Explain how missing data were addressed	5
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	5
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	6
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	7,8
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8
		(b) Report category boundaries when continuous variables were categorized	8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	8

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10-12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Population-based cohort study examining the association between splenectomy and empyema in adults in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015101.R4
Article Type:	Research
Date Submitted by the Author:	05-Jul-2017
Complete List of Authors:	Lin, Hsien-Feng; China Medical University Hospital, ; Liao, Kuan-Fu Chang, Ching-Mei Lin, Cheng-Li Lai, Shih-Wei; China Medical University Hospital, Department of Family Medicine
<b>Primary Subject Heading</b>:	General practice / Family practice
Secondary Subject Heading:	Gastroenterology and hepatology
Keywords:	empyema, splenectomy, Taiwan National Health Insurance Program

SCHOLARONE™  
Manuscripts

1  
2  
3 **Population-based cohort study examining the association between splenectomy**  
4 **and empyema in adults in Taiwan**  
5  
6

7  
8 □ Running head: splenectomy and empyema

9 • Authors' full names:

10 Hsien-Feng Lin MD and MS<sup>1,2</sup>; Kuan-Fu Liao MD and PhD<sup>3,4,5</sup>; Ching-Mei  
11 Chang RN and MSN<sup>6</sup>; Cheng-Li Lin MS<sup>7,8</sup>; Shih-Wei Lai MD<sup>2,7</sup>

- 12  
13 • (The first three authors contributed equally to this study)  
14  
15 • <sup>1</sup>School of Chinese Medicine, <sup>5</sup>Graduate Institute of Integrated Medicine, and  
16 <sup>7</sup>College of Medicine, China Medical University, Taichung, Taiwan.  
17  
18 • <sup>3</sup>Department of Internal Medicine, Taichung Tzu Chi General Hospital,  
19 Taichung, Taiwan  
20  
21 • <sup>4</sup>College of Medicine, Tzu Chi University, Hualien, Taiwan  
22  
23 • <sup>2</sup>Department of Family Medicine and <sup>8</sup>Management Office for Health Data,  
24 China Medical University Hospital, Taichung, Taiwan.  
25  
26 • <sup>6</sup>Assistant Professor and Deputy Director, Department of Nursing, Tungs'  
27 Taichung Metro Harbor Hospital, Taichung, Taiwan  
28  
29 • Corresponding author: Shih-Wei Lai, Department of Family Medicine, China  
30 Medical University Hospital, No 2, Yuh-Der Road, Taichung City, 404,  
31 Taiwan  
32 Phone: 886-4-2205-2121; Fax: 886-4-2203-3986  
33 E-mail: wei@mail.cmuh.org.tw  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective.** This study aimed to investigate the association between splenectomy and empyema in Taiwan. **Methods.** A population-based cohort study was conducted using the hospitalization dataset of the Taiwan National Health Insurance Program. A total of 13193 subjects aged 20–84 years who were newly diagnosed with splenectomy from 2000 to 2010 were enrolled in the splenectomy group and 52464 randomly selected subjects without splenectomy were enrolled in the non-splenectomy group. Both groups were matched by sex, age, comorbidities, and the index year of undergoing splenectomy. The incidence of empyema at the end of 2011 was calculated. A multivariable Cox proportional hazards regression model was used to estimate the hazard ratio (HR) with 95% confidence interval (CI) of empyema associated with splenectomy and other comorbidities. **Results.** The overall incidence rate of empyema was 2.56-fold higher in the splenectomy group than in the non-splenectomy group (8.85 vs. 3.46 per 1,000 person-years). The Kaplan–Meier analysis revealed a higher cumulative incidence of empyema in the splenectomy group than in the non-splenectomy group (6.99% vs. 3.37% at the end of follow-up). After adjusting for confounding variables, the adjusted HR of empyema was 2.89 for the splenectomy group compared with that for the non-splenectomy group. Further analysis revealed that HR of empyema was 4.52 for subjects with splenectomy alone. **Conclusion.** The incidence rate ratio between the splenectomy and non-splenectomy groups reduced from 2.87 in the first 5 years of follow-up to 1.73 in the period following the 5 years. Future studies are required to confirm whether a longer follow-up period would further reduce this average ratio. For the splenectomy group, the overall HR of developing empyema was 2.89 after adjusting for age, sex, and comorbidities, which was identified from previous literature. The risk of empyema following splenectomy remains high despite the absence of these comorbidities.

**Keywords:** empyema; splenectomy; Taiwan National Health Insurance Program

### Strengths and limitations of this study.

1. This is the first original study on the association between splenectomy and empyema.
2. We used a hospitalization dataset with a large sample size and great statistical power.
3. Some traditional behavior risk factors including alcohol consumption and cigarette smoking were not recorded due to the inherent limitation of this insurance database.
4. This case-control study included only patients with splenectomy, which may limit

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

the generalisability of the study results to the general population.

- 5. Such a study design does not permit to conclude a substantial causality.

For peer review only



## INTRODUCTION

Pleural empyema is a suppurative infection of the pleural cavity. The etiology of empyema is classified as two distinct mechanisms. Empyema most commonly occurs following pneumonia as microorganisms spread directly into the pleural cavity. This occurs in approximately 1%–5% of pneumonia cases.<sup>1,2</sup> The second mechanism occurs following surgery, most commonly of the thorax, esophagus, lung, or heart. Although empyema is an ancient disease with centuries of learned experience, it continues to be an important clinical problem. Despite the use of antibiotics and different pneumococcal vaccines, empyema remains the most common complication of pneumonia and is an important cause of morbidity worldwide.<sup>3</sup> The development of antibiotics in the first half of the 20th century significantly contributed in decreasing the incidence of pleural infection. However, this trend shifted at the end of the 20th century, and the incidence of empyema has tended to increase worldwide.

The human spleen mainly serves as an immune responder against invading microorganisms.<sup>4,5</sup> Immunologic responses and hematologic functions of the human spleen is well-known. The spleen, mediated by the innate and adaptive immunity, protects the body against infections.<sup>6,7</sup> Therefore, patients with splenectomy are more likely than those without splenectomy to develop severe life-threatening infections. Splenectomy is associated with an increased risk of some diseases, including pulmonary tuberculosis, type 2 diabetes mellitus, pyogenic liver abscess, renal and perinephric abscesses, and acute pancreatitis;<sup>8-12</sup> however, to our knowledge, post-splenectomy empyema has not yet been studied.

Despite the trend of increasing incidence of empyema worldwide, no study has evaluated the association between splenectomy and empyema. Here we rationally hypothesize an association between splenectomy and empyema owing to the immunocompromized condition induced by splenectomy, which can further increase

1  
2  
3 the risk of microorganism invasion of the pleural cavity. However, there is limited  
4 published literature regarding epidemiological studies on this issue. As splenectomy is  
5 associated with overwhelming post-splenectomy infections and empyema carries  
6 potential fatality, exploring the risk of empyema in patients with splenectomy may  
7 have significant clinical and public health implications. Therefore, to explore whether  
8 an association between splenectomy and empyema exists, we conducted a nationwide  
9 cohort study using the hospitalization dataset of the Taiwan National Health Insurance  
10 Program.  
11  
12  
13  
14  
15  
16  
17  
18  
19

## 20 **METHODS**

### 21 **Study design and data source**

22  
23  
24  
25 Taiwan is an independent country with over 23 million people.<sup>13-17</sup> We conducted a  
26 population-based cohort study using insurance claim data from the Taiwan National  
27 Health Insurance Program, which has covered 99% of the Taiwan population since  
28 1995 and thus is a thorough representative sample of the population.<sup>18</sup> The details of  
29 the insurance program have been well-documented in previous studies.<sup>19-22</sup> This study  
30 was approved by the Research Ethics Committee of China Medical University and  
31 Hospital in Taiwan (CMUH-104-REC2-115).  
32  
33  
34  
35  
36  
37  
38  
39

### 40 **Study subjects**

41  
42 Using the hospitalization dataset of the Taiwan National Health Insurance Program,  
43 all hospitalized subjects aged 20–84 years who underwent splenectomy (International  
44 Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9 procedure  
45 code 41.5) between January 1, 2000 and December 31, 2010 were categorized in the  
46 splenectomy group. The year of undergoing splenectomy was defined as the index  
47 year. For each subject in the splenectomy group, four subjects who did not undergo  
48 splenectomy were randomly selected from the same database and were categorized in  
49 the non-splenectomy group. Both groups were matched with regard to sex, age (every  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 5-year span), comorbidities, and the index year of undergoing splenectomy. To reduce  
4  
5 potentially biased results, subjects with an empyema diagnosis (ICD-9 codes 510,  
6  
7 511.1, 511.8, and 511.9) within 1 month following splenectomy were excluded.  
8  
9

### 10 **Outcome and Comorbidities**

11 The main outcome was a new diagnosis of empyema on the basis of hospital  
12  
13 discharge registries during the follow-up period. Each subject was monitored from the  
14  
15 index year until being diagnosed with empyema; being censored because of the loss to  
16  
17 follow-up, death, or withdrawal from insurance; or at the end of December 31, 2011,  
18  
19 namely the end of the study. The following comorbidities were investigated:  
20  
21 alcohol-related disease, cancer, chronic kidney disease, chronic liver disease  
22  
23 (including cirrhosis, alcoholic liver damage, hepatitis B, hepatitis C, and other chronic  
24  
25 hepatitis), chronic obstructive pulmonary disease, and diabetes mellitus. All  
26  
27 comorbidities were diagnosed according to the ICD-9 codes, which have been well  
28  
29 assessed in previous studies.<sup>23-33</sup>  
30  
31  
32  
33

### 34 **Statistical analysis**

35  
36 The differences between the splenectomy and non-splenectomy groups with respect  
37  
38 to sex, age, and comorbidities were compared using chi-square test for categorical  
39  
40 variables and t-test for continuous variables. The subject's sex, age, and follow-up  
41  
42 period (in person-years) were used to estimate incidence rate and incidence rate ratio  
43  
44 (IRR) of the splenectomy group to the non-splenectomy group with 95% confidence  
45  
46 interval (CI) using Poisson regression. Multivariable Cox proportional hazards  
47  
48 regression model was used to estimate the hazard ratio (HR) with 95% CI of  
49  
50 empyema associated with splenectomy and other comorbidities, after simultaneously  
51  
52 adjusting for confounding variables in the univariable Cox proportional hazard  
53  
54 regression model. The proportional hazard model assumption was examined using a  
55  
56 test of scaled Schoenfeld residuals. The results of the model that evaluated the risk of  
57  
58  
59  
60

1  
2  
3 empyema throughout the follow-up period revealed a significant association between  
4  
5 Schoenfeld residuals for splenectomy and follow-up period, suggesting that the  
6  
7 proportionality assumption was violated ( $P < 0.001$ ). In the subsequent analysis, we  
8  
9 stratified the follow-up period to avoid violation of the proportional hazard  
10  
11 assumption. All statistical analyses were performed using SAS 9.2 (SAS Institute,  
12  
13 Cary, North Carolina, USA). Two-tailed P values of  $<0.05$  were considered to be  
14  
15 statistically significant.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

### Baseline data of the study subjects

Table 1 shows the baseline data of the study subjects. A total of 13193 subjects with splenectomy and 52464 subjects without splenectomy were included, with similar distributions in sex and age. Mean ages (mean  $\pm$  standard deviation) were  $52.8 \pm 17.2$  years in the splenectomy group and  $52.5 \pm 17.2$  years in the non-splenectomy group (t-test;  $P = 0.05$ ). Mean follow-up periods (mean  $\pm$  standard deviation) were  $4.37 \pm 3.44$  person-years in the splenectomy group and  $5.75 \pm 3.32$  person-years in the non-splenectomy group (t-test;  $P < 0.001$ ). There was no significant difference in the prevalence of comorbidities between the splenectomy and non-splenectomy groups (chi-square test;  $P > 0.05$  for all).

### Incidence of empyema stratified by sex, age, and follow-up period

Table 2 shows the incidence rates of empyema. At the end of the cohort study, the overall incidence rate of empyema was 2.56-fold higher in the splenectomy group than in the non-splenectomy group (8.85 vs. 3.46 per 1,000 person-years; 95% CI, 2.44–2.69). The incidence rate of empyema, stratified by sex, age, and follow-up period, was higher in the splenectomy group than in the non-splenectomy group. The incidence rate of empyema increased with age in both the groups, with the highest rate reported in the splenectomy group with subjects aged 65–84 years (19.2 per 1,000 person-years). Stratified analysis by follow-up period revealed that the incidence rate of empyema decreased with the follow-up period in both the groups. The risk of empyema in the splenectomy group was significantly higher in the first 5 years of follow-up (IRR, 2.87; 95% CI, 2.73–3.01). However, risk of empyema continued to exist in the splenectomy group even after 5 years (IRR, 1.73; 95% CI, 1.60–1.88).

The Kaplan–Meier model revealed a higher cumulative incidence of pleural empyema in the splenectomy group than in the non-splenectomy group (6.99% vs.

1  
2  
3 3.37% at the end of follow-up;  $P < 0.001$ ; Figure 1).  
4  
5  
6

### 7 **HR of empyema associated with splenectomy and other comorbidities**

8  
9  
10 Table 3 displays HR of empyema associated with splenectomy and other  
11 comorbidities. Variables that were found to be statistically significant in the  
12 univariable model were further examined in the multivariable model. After adjusting  
13 for age, sex, alcohol-related disease, cancers, chronic kidney disease, chronic liver  
14 disease, chronic obstructive pulmonary disease, and diabetes mellitus, the  
15 multivariable Cox proportional hazards regression model revealed that the adjusted  
16 HR of empyema was 2.89 in the splenectomy group (95% CI, 2.60–3.22) compared  
17 with that in the non-splenectomy group.  
18  
19  
20  
21  
22  
23  
24  
25  
26

### 27 **Interaction effect between splenectomy and other comorbidities on the risk of** 28 **empyema**

29  
30  
31 Table 4 displays the interaction effect between splenectomy and other  
32 comorbidities, including alcohol-related diseases, cancers, chronic kidney disease,  
33 chronic liver diseases, chronic obstructive pulmonary diseases, and diabetes mellitus,  
34 on the risk of empyema. The adjusted HR of empyema was 4.52 for subjects with  
35 splenectomy alone and without any comorbidity (95% CI, 3.80–5.37). HR markedly  
36 increased to 8.23 for subjects with splenectomy and with any comorbidity (95% CI,  
37 6.98–9.70), demonstrating an interaction effect between splenectomy and other  
38 comorbidities on the risk of empyema.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

Sinwar<sup>34</sup> found that the duration between splenectomy and the onset of overwhelming post-splenectomy infections could range from <1 week to >20 years. To reduce biased results, patients who underwent splenectomy within 1 month of empyema diagnosis were excluded to ensure that splenectomy truly preceded the onset of empyema.

Extensive evidence has supported the protective role of the human spleen against invading microorganisms on the basis of the bactericidal capacity of lymphoid cells and macrophages, as well as humoral immune response.<sup>6,35-37</sup> Following splenectomy, normal immune functions such as phagocytic activity and humoral immune response may be significantly changed. Therefore, impaired post-splenectomy immune functions may increase the risk of a life-threatening infection and empyema. In our study, the risk of empyema in the splenectomy group was higher in the first 5 years of follow-up than after the first 5 years (IRR, 2.87 vs 1.73). However, the risk of empyema continued to exist in the splenectomy group, even after the first 5 years. These findings are compatible with previously reported findings that revealed that the majority of severe infections occur within the first 3 years following splenectomy; although the risk declines over time, it may last for >5 years following splenectomy.<sup>38-40</sup> However, the exact mechanism underlying this risk remains unknown. We speculate that with time, the immune system may develop compensatory mechanisms that may overcome these immune deficits. Future studies are required to confirm this hypothesis.

To the best of our knowledge, this population-based cohort study is the first to reveal that splenectomy is associated with an increased HR of empyema (adjusted HR, 2.89). Some studies have reported that splenectomy is associated with an increased risk of diseases. Lai et al. compared between splenectomy patients and

1  
2  
3 non-splenectomy patients and found that for post-splenectomy patients, the adjusted  
4 odds ratio of acute pancreatitis was 2.90 (95% CI, 1.39–6.05),<sup>12</sup> the adjusted HR of  
5 renal and perinephric abscesses was 2.24 (95% CI, 1.30–3.88),<sup>11</sup> the adjusted HR of  
6 pyogenic liver abscess was 3.89 (95% CI, 3.20–4.72),<sup>10</sup> and the odds ratio of  
7 pulmonary tuberculosis were 1.91 (95% CI, 1.06–3.44).<sup>8</sup>

8  
9  
10  
11  
12  
13  
14 In this study, after adjusting for potential confounding variables, we also observed  
15 that the splenectomy group was at an increased risk of empyema (adjusted HR, 2.89).  
16 This phenomenon would typically be regarded as counterintuitive, but the exact  
17 reason remains unclear. A possible reason can be that some comorbidities that are  
18 potentially associated with empyema should have been included in the study; however,  
19 further studies are required to explain this phenomenon. The HR was higher than that  
20 observed for comorbidities. HR was not confounded by comorbidities because there  
21 was no significant difference in the prevalence of comorbidities between the  
22 splenectomy and non-splenectomy groups. This indicates that the increased HR of  
23 empyema in patients with splenectomy cannot be completely attributed to the  
24 prevalence of comorbidities. Although these comorbidities were found to be  
25 associated with empyema, to minimize their confounding effects, a further analysis  
26 was conducted. It was noted that in absence of any comorbidity, patients with  
27 splenectomy continued to have a higher HR of empyema (HR, 4.52). These results  
28 indicate that even in the absence of comorbidities, splenectomy may have a unique  
29 role in the risk of developing empyema. These findings are compatible with  
30 previously reported findings in the literature, in which patients with splenectomy are  
31 more prone to have severe life-threatening infections owing to an  
32 immunocompromized condition following splenectomy<sup>41,42</sup> and are at an increased  
33 risk of developing empyema.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

57  
58 The limitations of this study as follows. First, some traditional behavior risk factors,  
59



1  
2  
3 including alcohol consumption and cigarette smoking, were not considered owing to  
4  
5 inherent limitations of the insurance database. We used alcohol-related diseases  
6  
7 instead of alcohol consumption and chronic obstructive pulmonary disease instead of  
8  
9 cigarette smoking. Second, the underlying causes for splenectomy were also not  
10  
11 recorded owing to limitation of the database. Splenectomy is common in certain  
12  
13 disorders and diseases such as hematological disorders, gastric cancer, or trauma; thus,  
14  
15 these background conditions may confound the results. We could not clarify the  
16  
17 association of the cause of splenectomy with the development of empyema in this  
18  
19 study. Third, owing to the limitation of the database, the underlying causes for  
20  
21 splenectomy were not recorded. The cause of splenectomy could be the cause of  
22  
23 empyema, for example, splenic abscess. Considering the high quality of the Taiwan  
24  
25 medical system, 1 month is not required to confirm empyema diagnosis from the  
26  
27 onset of empyema prodrome. To reduce biased results, subjects with an empyema  
28  
29 diagnosis within 1 month following splenectomy were excluded. Therefore, it is less  
30  
31 likely that splenectomy is the cause of empyema. Fourth, empyema could very well  
32  
33 correlate with open surgery. However, owing to the previously mentioned limitations,  
34  
35 the splenectomy type was not recorded. It is not known if splenectomy was performed  
36  
37 via open or laparoscopic surgery or if it was a total or partial splenectomy. Fifth, the  
38  
39 lack of vaccination could very well correlate with empyema. However, the number of  
40  
41 subjects with splenectomy who were vaccinated against encapsulated bacteria  
42  
43 (particularly *Streptococcus pneumoniae*) was unknown; thus, we could not investigate  
44  
45 whether pneumococcal vaccination decreased the risk of empyema. Sixth, as  
46  
47 causative pathogens were not recorded, the types of bacteria that contributed to  
48  
49 empyema development could not be investigated. The lack of such data did not permit  
50  
51 us to conclude a substantial causality. This case-control study included only patients  
52  
53 with splenectomy, which may limit the generalisability of the study results to the  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 general population. Such a study design does not permit to conclude a substantial  
5  
6 causality. Further prospective studies are required to confirm the findings of our  
7  
8 study.

9  
10 To the best of our knowledge, this is the first original study to describe the  
11  
12 association between splenectomy and empyema. Although the underlying  
13  
14 mechanisms that associate splenectomy and empyema could not be completely  
15  
16 determined, our findings are novel and clinically important. In addition, we used a  
17  
18 hospitalization dataset that had a large sample size and substantial statistical power.  
19  
20 The diagnosis codes of the included comorbidities have been previously documented.  
21  
22 <sup>23-33</sup> The study design and statistical methodology are described in detail, and our  
23  
24 results are relatively promising. Because the splenectomy and non-splenectomy  
25  
26 groups had similar distributions of the studied comorbidities, the confounding effects  
27  
28 of the comorbidities on the risk of empyema appear to be minimal.

29  
30  
31 The incidence rate ratio between the splenectomy and non-splenectomy groups  
32  
33 reduced from 2.87 in the first 5 years of follow-up to 1.73 in the period following the  
34  
35 5 years. Future studies are required to confirm whether a longer follow-up period  
36  
37 would further reduce this average ratio. For the splenectomy group, the overall HR of  
38  
39 developing empyema was 2.89 after adjusting for age, sex, and comorbidities, which  
40  
41 were identified from previous literature (including alcohol-related disease, cancer,  
42  
43 chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease,  
44  
45 and diabetes mellitus). The risk of empyema following splenectomy remains high  
46  
47 despite the absence of these comorbidities.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Data sharing statement:** no additional data available

### **Acknowledgement**

This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW106-TDU-B-212-113004), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10601010036), Taiwan Clinical Trial Consortium for Stroke(MOST 106-2321-B-039-005), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyoko Aoshima Memorial Funds, Japan. These funding agencies did not influence the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### **Specific author contributions**

Hsien-Feng Lin and Kuan-Fu Liao planned and conducted this study, participated in the data interpretation, and revised the article.

Ching-Mei Chang and Cheng-Li Lin conducted the data analysis and revised the article.

Shih-Wei Lai planned and conducted this study, contributed to the conception of the article, initiated the draft of the article, and revised the article.

### **Conflict of Interest Statement**

The authors disclose no conflicts of interest.

### **Funding statement**

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors

**REFERENCES**

1. Ahmed RA, Marrie TJ, Huang JQ. Thoracic empyema in patients with community-acquired pneumonia. *Am J Med* 2006;119:877-83.
2. Shields T, Locicero J, Ponn R, Rusch V, eds. *General Thoracic Surgery*, 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2005:823.
3. Septimus EJ. Pleural effusion and empyema. In: Mandell GL, Bennet JE, Mandell RD, editors. *Douglas and Bennett's principles and practice of infectious diseases*. Edinburgh: Churchill Livingstone; 2009. pp. 917-24.
4. Spencer RP, Pearson HA. The spleen as a hematological organ. *Semin Nucl Med*. 1975;5:95-102.
5. Trigg ME. Immune function of the spleen. *South Med J*. 1979;72:593-9.
6. Jirillo E, Mastronardi ML, Altamura M, Munno I, Miniello S, Urgesi G, et al. The immunocompromised host: immune alterations in splenectomized patients and clinical implications. *Curr Pharm Des*. 2003;9:1918-23.
7. Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. *Lancet*. 2011;378:86-97.
8. Lai SW, Wang IK, Lin CL, Chen HJ, Liao KF. Splenectomy correlates with increased risk of pulmonary tuberculosis: a case-control study in Taiwan. *Clin Microbiol Infect* 2014;20:764-7.
9. Wu SC, Fu CY, Muo CH, Chang YJ. Splenectomy in trauma patients is associated with an increased risk of postoperative type II diabetes: a nationwide population-based study. *Am J Surg* 2014;208:811-6.
10. Lai SW, Lai HC, Lin CL, Liao KF. Splenectomy Correlates With Increased Risk of Pyogenic Liver Abscess: A Nationwide Cohort Study in Taiwan. *J Epidemiol* 2015;25:561-6.
11. Lai SW, Lin HF, Lin CL, Liao KF. Splenectomy and risk of renal and perinephric abscesses: A population-based cohort study in Taiwan. *Medicine* 2016;95:31(e4438).
12. Lai SW, Lin CL, Liao KF. Splenectomy Correlates With Increased Risk of Acute Pancreatitis: A Case-Control Study in Taiwan. *J Epidemiol* 2016;26:488-92.
13. Liu WH, Liu TC, Mong MC. Antibacterial effects and action modes of asiatic acid. *Biomedicine-Taiwan*. 2015;5:22-9.
14. Lin CJ, Lai CK, Kao MC, Wu LT, Lo UG, Lin LC, et al. Impact of cholesterol on disease progression. *Biomedicine-Taiwan*. 2015;5:1-7.
15. Lin CH, Li TC, Tsai PP, Lin WC. The relationships of the pulmonary arteries to lung lesions aid in differential diagnosis using computed tomography. *Biomedicine-Taiwan*. 2015;5:31-8.

16. Li TC, Li CI, Liao LN, Liu CS, Yang CW, Lin CH, et al. Associations of EDNRA and EDN1 polymorphisms with carotid intima media thickness through interactions with gender, regular exercise, and obesity in subjects in Taiwan: Taichung Community Health Study (TCHS). *Biomedicine-Taiwan*. 2015;5:8-14.
17. Chen HX, Lai CH, Hsu HY, Huang JC, Wu HS, Ho MW, et al. The bacterial interactions in the nasopharynx of children receiving adenoidectomy. *Biomedicine-Taiwan*. 2015;5:39-43.
18. National Health Insurance Research Database. Taiwan. <http://nhird.nhri.org.tw/en/index.html> [cited in March 1, 2017, English version].
19. Lai SW, Liao KF, Liao CC, Muo CH, Liu CS, Sung FC. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. *Medicine* 2010;89:295-9.
20. Chen HY, Lai SW, Muo CH, Chen PC, Wang IJ. Ethambutol-induced optic neuropathy: a nationwide population-based study from Taiwan. *Br J Ophthalmol* 2012;96:1368-71.
21. Yang SP, Muo CH, Wang IK, et al. Risk of type 2 diabetes mellitus in female breast cancer patients treated with morphine: A retrospective population-based time-dependent cohort study. *Diabetes Res Clin Pract* 2015;110:285-90.
22. Tsai TY, Lin CC, Peng CY, et al. The association between biliary tract inflammation and risk of digestive system cancers: A population-based cohort study. *Medicine* 2016;95: e4427.
23. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. *Am J Gastroenterol* 2012;107:46-52.
24. Liao KF, Lin CL, Lai SW, Chen WC. Zolpidem Use Associated With Increased Risk of Pyogenic Liver Abscess: A Case-Control Study in Taiwan. *Medicine* 2015;94:e1302.
25. Wong TS, Liao KF, Lin CM, Lin CL, Chen WC, Lai SW. Chronic Pancreatitis Correlates With Increased Risk of Cerebrovascular Disease: A Retrospective Population-Based Cohort Study in Taiwan. *Medicine* 2016;95:e3266.
26. Liao KF, Lai SW, Lin CL, Chien SH. Appendectomy correlates with increased risk of pyogenic liver abscess: A population-based cohort study in Taiwan. *Medicine* 2016;95:e4015.
27. Cheng KC, Lin WY, Liu CS, Lin CC, Lai HC, Lai SW. Association of different types of liver disease with demographic and clinical factors. *BioMedicine-Taiwan* 2016;6:16-22.
28. Liao KF, Cheng KC, Lin CL, Lai SW. Etodolac and the risk of acute pancreatitis. *BioMedicine-Taiwan* 2017;7:25-9.

- 1
- 2
- 3 29. Shen ML, Liao KF, Tsai SM, Lin CL, Lai SW. Herpes zoster correlates with
- 4 pyogenic liver abscesses in Taiwan. *BioMedicine-Taiwan* 2016;6:24-9.
- 5
- 6 30. Lai SW. Risks and benefits of zolpidem use in Taiwan: a narrative review.
- 7 *BioMedicine-Taiwan* 2016;6:9-11.
- 8
- 9 31. Cheng KC, Lee TL, Lin YJ et al. Facility evaluation of resigned hospital
- 10 physicians:managerial implications for hospital physician manpower. *Biomedicine*
- 11 *2016; 6: 30-9.*
- 12
- 13 32. Lai SW, Lin CL, Liao KF. Risk of contracting pneumonia among patients with
- 14 predialysis chronic kidney disease: a population-based cohort study in Taiwan.
- 15 *BioMedicine-Taiwan* 2017; 7: 42-47.
- 16
- 17 33. Liao KF, Huang PT, Lin CC, Lin CL, Lai SW. Fluvastatin use and risk of acute
- 18 pancreatitis:a population-based case-control study in Taiwan.
- 19 *BioMedicine-Taiwan* 2017;7: 24-28.
- 20
- 21 34. Sinwar PD. Overwhelming post splenectomy infection syndrome—review study.
- 22 *Int J Surg.* 2014;12:1314–6.
- 23
- 24 35. Eibl M. Immunological consequences of splenectomy. *Prog Pediatr Surg.*
- 25 1985;18:139–45.
- 26
- 27 36. Van Rooijen N. The humoral immune response in the spleen. *Res Immunol.*
- 28 1991;142:328–30.
- 29
- 30 37. Altamura M, Caradonna L, Amati L, Pellegrino NM, Urgesi G, Miniello S.
- 31 Splenectomy and sepsis: the role of the spleen in the immune-mediated bacterial
- 32 clearance. *Immunopharmacol Immunotoxicol.* 2001;23:153–61.
- 33
- 34 38. Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among
- 35 post-splenectomy patients. *J Infect.* 2001;43:182–6.
- 36
- 37 39. Kyaw MH, Holmes EM, Toolis F, Wayne B, Chalmers J, Jones IG, et al.
- 38 Evaluation of severe infection and survival after splenectomy. *Am J Med.*
- 39 2006;119:276 e1–7.
- 40
- 41 40. Dendle C, Sundararajan V, Spelman T, Jolley D, Woolley I. Splenectomy
- 42 sequelae: an analysis of infectious outcomes among adults in Victoria. *Med J Aust.*
- 43 2012;196:582–6.
- 44
- 45 41. Di Cataldo A, Puleo S, Li Destri G, Racalbutto A, Trombatore G, Latteri F, et al.
- 46 Splenic trauma and overwhelming postsplenectomy infection. *Br J Surg.*
- 47 1987;74:343–5.
- 48
- 49 42. Lynch AM, Kapila R. Overwhelming postsplenectomy infection. *Infect Dis Clin*
- 50 *North Am.* 1996;10:693–707.
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

**Table 1. Baseline characteristics between splenectomy group and non-splenectomy group**

Variable	Splenectomy				<i>P</i> value*
	No		Yes		
	N=52464		N=13193		
	N	%	n	%	
Sex					0.88
Female	20431	38.9	5128	38.9	
Male	32033	61.1	8065	61.1	
Age group (years)					0.98
20–39	13415	25.6	3364	25.5	
40–64	24112	46.0	6062	46.0	
65–84	14937	28.5	3767	28.6	
Age (years), mean (standard deviation) <sup>†</sup>	52.5	(17.2)	52.8	(17.2)	0.05
Follow-up period (years), mean (standard deviation) <sup>†</sup>	5.75	(3.32)	4.37	(3.44)	< 0.001
Baseline comorbidities					
Alcohol-related disease	1787	3.41	452	3.43	0.91
Cancer	7677	14.6	1962	14.9	0.49
Chronic kidney disease	1068	2.04	270	2.05	0.94
Chronic liver disease	7791	14.9	1971	14.9	0.80
Chronic obstructive pulmonary disease	2002	3.82	507	3.84	0.89
Diabetes mellitus	7856	15.0	1983	15.0	0.87

Data are presented as the number of subjects in each group, with percentages given in parentheses, or mean with standard deviation given in parentheses.

\*Chi-square test, and <sup>†</sup>*t*-test comparing subjects with and without splenectomy.

**Table 2. Incidence density of empyema estimated by sex, age, and follow-up period between splenectomy group and non-splenectomy group**

Variable	Non-splenectomy				Splenectomy				IRR <sup>#</sup> (95% CI)
	N	Cases	Person-years	Incidence <sup>†</sup>	N	Cases	Person-years	Incidence <sup>†</sup>	
All	52464	1042	301484	3.46	13193	510	57622	8.85	2.56 (2.44,2.69)
Sex									
Female	20431	317	119441	2.65	5128	159	23004	6.91	2.60 (2.40, 2.82)
Male	32033	725	182042	3.98	8065	351	34618	10.1	2.55 (2.39, 2.71)
Age group (years)									
20–39	13415	57	84004	0.68	3364	65	19700	3.30	4.86 (4.39, 5.39)
40–64	24112	354	140554	2.52	6062	224	26423	8.48	3.37 (3.13, 3.62)
65-84	14937	631	76925	8.20	3767	221	11499	19.2	2.34 (2.14, 2.56)
Follow-up period (years)									
< 5	52464	720	206010	3.49	13193	416	41545	10.0	2.87 (2.73, 3.01)
≥ 5	28456	322	95474	3.37	5052	94	16077	5.85	1.73 (1.60, 1.88)

<sup>†</sup> Incidence rate: per 1,000 person-years.

<sup>#</sup>IRR (incidence rate ratio): splenectomy vs. non-splenectomy (95% confidence interval)



**Table 3. Adjusted hazard ratio and 95% confidence interval of empyema associated with splenectomy and other comorbidities**

Variable	Crude	Adjusted <sup>†</sup>
	HR (95%CI)	HR (95%CI)
Sex (male vs. female)	1.48 (1.33, 1.65)	1.51 (1.35, 1.68)
Age (per one year)	1.05 (1.04, 1.05)	1.05 (1.05, 1.06)
Baseline comorbidities (yes vs. no)		
<b>Splenectomy</b>	<b>2.52 (2.26, 2.80)</b>	<b>2.89 (2.60, 3.22)</b>
Alcohol-related disease	1.61 (1.28, 2.03)	2.25 (1.76, 2.86)
Cancer	2.60 (2.31, 2.92)	1.92 (1.71, 2.17)
Chronic kidney disease	3.04 (2.40, 3.85)	2.13 (1.67, 2.70)
Chronic liver disease	2.07 (1.84, 2.34)	1.90 (1.68, 2.14)
Chronic obstructive pulmonary disease	3.95 (3.37, 4.64)	1.75 (1.48, 2.07)
Diabetes mellitus	2.80 (2.51, 3.13)	1.85 (1.65, 2.07)

<sup>†</sup>Variables found to be statistically significant in the univariable model were further examined in the multivariable model. Adjusted for age, sex, alcohol-related disease, cancer, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease, and diabetes mellitus

**Table 4. Cox proportional hazard regression analysis for risk of empyema stratified by splenectomy and comorbidities**

Variable		Event	Incidence <sup>†</sup>	Adjusted HR <sup>#</sup> (95% CI)
Splenectomy	Any comorbidity*			
No	No	299	1.49	1(Reference)
No	Yes	743	7.34	3.64(3.18, 4.17)
Yes	No	230	5.75	4.52(3.80, 5.37)
Yes	Yes	280	15.9	8.23(6.98, 9.70)

<sup>†</sup> Incidence rate: per 1,000 person-years

<sup>#</sup> Adjusted for sex and age


\*Comorbidities including alcohol-related disease, cancer, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease, and diabetes mellitus

95% CI: 95% confidence interval

1  
2  
3  
4  
5  
6 **Fig 1: Kaplan-Meier model revealed that the splenectomy group had a higher**  
7  
8 **cumulative incidence of pleural empyema than the non-splenectomy**  
9  
10 **group (6.99% vs. 3.37% at the end of follow-up;  $P < 0.001$ )**  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



190x107mm (300 x 300 DPI)

review only

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	
<b>Introduction</b>				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3	
Objectives	3	State specific objectives, including any prespecified hypotheses	3,4	
<b>Methods</b>				
Study design	4	Present key elements of study design early in the paper	4	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	4	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5	
Bias	9	Describe any efforts to address potential sources of bias	4,5	
Study size	10	Explain how the study size was arrived at	4	

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5
		(b) Describe any methods used to examine subgroups and interactions	5
		(c) Explain how missing data were addressed	5
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	5
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	6
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	7,8
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8
		(b) Report category boundaries when continuous variables were categorized	8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	8

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10-12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).